
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="8E59E75092657F733AE750002BD6D363.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="thebreast">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10165146/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="The Breast : Official Journal of the European Society of Mastology">
<meta name="citation_title" content="Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score">
<meta name="citation_author" content="Cong Feng">
<meta name="citation_author_institution" content="Department of Oncology, The Second Affiliated Hospital of Xi&#x27;an Jiaotong University, Xi&#x27;an, Shanxi, China">
<meta name="citation_author" content="Yinbin Zhang">
<meta name="citation_author_institution" content="Department of Oncology, The Second Affiliated Hospital of Xi&#x27;an Jiaotong University, Xi&#x27;an, Shanxi, China">
<meta name="citation_author" content="Fei Wu">
<meta name="citation_author_institution" content="Department of Oncology, The Second Affiliated Hospital of Xi&#x27;an Jiaotong University, Xi&#x27;an, Shanxi, China">
<meta name="citation_author" content="Jia Li">
<meta name="citation_author_institution" content="Department of Oncology, The Second Affiliated Hospital of Xi&#x27;an Jiaotong University, Xi&#x27;an, Shanxi, China">
<meta name="citation_author" content="Mengjie Liu">
<meta name="citation_author_institution" content="Department of Oncology, The Second Affiliated Hospital of Xi&#x27;an Jiaotong University, Xi&#x27;an, Shanxi, China">
<meta name="citation_author" content="Wei Lv">
<meta name="citation_author_institution" content="Department of Oncology, The Second Affiliated Hospital of Xi&#x27;an Jiaotong University, Xi&#x27;an, Shanxi, China">
<meta name="citation_author" content="Chaofan Li">
<meta name="citation_author_institution" content="Department of Oncology, The Second Affiliated Hospital of Xi&#x27;an Jiaotong University, Xi&#x27;an, Shanxi, China">
<meta name="citation_author" content="Weiwei Wang">
<meta name="citation_author_institution" content="Department of Oncology, The Second Affiliated Hospital of Xi&#x27;an Jiaotong University, Xi&#x27;an, Shanxi, China">
<meta name="citation_author" content="Qinghua Tan">
<meta name="citation_author_institution" content="Department of Orthopedic Surgery, The Second Affiliated Hospital of Xi&#x27;an Jiaotong University, Xi&#x27;an, Shanxi, China">
<meta name="citation_author" content="Xiaoyu Xue">
<meta name="citation_author_institution" content="Amoy Diagnostics Co. Ltd., Xi&#x27;an, Shanxi, China">
<meta name="citation_author" content="Xingcong Ma">
<meta name="citation_author_institution" content="Department of Oncology, The Second Affiliated Hospital of Xi&#x27;an Jiaotong University, Xi&#x27;an, Shanxi, China">
<meta name="citation_author" content="Shuqun Zhang">
<meta name="citation_author_institution" content="Department of Oncology, The Second Affiliated Hospital of Xi&#x27;an Jiaotong University, Xi&#x27;an, Shanxi, China">
<meta name="citation_publication_date" content="2023 Apr 21">
<meta name="citation_volume" content="69">
<meta name="citation_firstpage" content="392">
<meta name="citation_doi" content="10.1016/j.breast.2023.04.002">
<meta name="citation_pmid" content="37116400">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC10165146/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC10165146/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC10165146/pdf/main.pdf">
<meta name="description" content="Homologous recombination deficiency (HRD) phenotype will sensitize tumors to poly (ADP-ribose) polymerases inhibitors and platinum. However, previous studies did not focus on the prevalence of HRD among Chinese breast cancer (BC) patients. One ...">
<meta name="og:title" content="Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Homologous recombination deficiency (HRD) phenotype will sensitize tumors to poly (ADP-ribose) polymerases inhibitors and platinum. However, previous studies did not focus on the prevalence of HRD among Chinese breast cancer (BC) patients. One ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC10165146/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="10165146">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1016/j.breast.2023.04.002"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/main.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC10165146%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/10165146/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/10165146/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC10165146/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-thebreast.gif" alt="The Breast : Official Journal of the European Society of Mastology logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to The Breast : Official Journal of the European Society of Mastology" title="Link to The Breast : Official Journal of the European Society of Mastology" shape="default" href="https://www.journals.elsevier.com/the-breast" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Breast</button></div>. 2023 Apr 21;69:392–400. doi: <a href="https://doi.org/10.1016/j.breast.2023.04.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1016/j.breast.2023.04.002</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22Breast%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Breast%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Breast%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Breast%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score<sup><a href="#d35e1126" class="usa-link">☆</a></sup>
</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Feng%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Cong Feng</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Cong Feng</span></h3>
<div class="p">
<sup>a</sup>Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Feng%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Cong Feng</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Yinbin Zhang</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Yinbin Zhang</span></h3>
<div class="p">
<sup>a</sup>Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yinbin Zhang</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wu%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Fei Wu</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Fei Wu</span></h3>
<div class="p">
<sup>a</sup>Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wu%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Fei Wu</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Jia Li</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Jia Li</span></h3>
<div class="p">
<sup>a</sup>Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jia Li</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Mengjie Liu</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Mengjie Liu</span></h3>
<div class="p">
<sup>a</sup>Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mengjie Liu</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lv%20W%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Wei Lv</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Wei Lv</span></h3>
<div class="p">
<sup>a</sup>Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lv%20W%22%5BAuthor%5D" class="usa-link"><span class="name western">Wei Lv</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Chaofan Li</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Chaofan Li</span></h3>
<div class="p">
<sup>a</sup>Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Chaofan Li</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20W%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Weiwei Wang</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Weiwei Wang</span></h3>
<div class="p">
<sup>a</sup>Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20W%22%5BAuthor%5D" class="usa-link"><span class="name western">Weiwei Wang</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tan%20Q%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Qinghua Tan</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Qinghua Tan</span></h3>
<div class="p">
<sup>b</sup>Department of Orthopedic Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tan%20Q%22%5BAuthor%5D" class="usa-link"><span class="name western">Qinghua Tan</span></a>
</div>
</div>
<sup>b</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xue%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Xiaoyu Xue</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Xiaoyu Xue</span></h3>
<div class="p">
<sup>c</sup>Amoy Diagnostics Co. Ltd., Xi'an, Shanxi, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xue%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xiaoyu Xue</span></a>
</div>
</div>
<sup>c</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ma%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Xingcong Ma</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Xingcong Ma</span></h3>
<div class="p">
<sup>a</sup>Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ma%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xingcong Ma</span></a>
</div>
</div>
<sup>a,</sup><sup>∗∗</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Shuqun Zhang</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Shuqun Zhang</span></h3>
<div class="p">
<sup>a</sup>Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Shuqun Zhang</span></a>
</div>
</div>
<sup>a,</sup><sup>∗</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup>a</sup>Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China</div>
<div id="aff2">
<sup>b</sup>Department of Orthopedic Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China</div>
<div id="aff3">
<sup>c</sup>Amoy Diagnostics Co. Ltd., Xi'an, Shanxi, China</div>
<div class="author-notes p">
<div class="fn" id="cor1">
<sup>∗</sup><p class="display-inline">Corresponding author. <span>shuqun_zhang1971@163.com</span></p>
</div>
<div class="fn" id="cor2">
<sup>∗∗</sup><p class="display-inline">Corresponding author. <span>cameo1190@163.com</span></p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2023 Feb 25; Revised 2023 Apr 13; Accepted 2023 Apr 15; Collection date 2023 Jun.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2023 The Authors. Published by Elsevier Ltd.</div>
<p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC10165146  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37116400/" class="usa-link">37116400</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abs0010"><h2>Abstract</h2>
<section id="sec1_pmc"><h3 class="pmc_sec_title">Background</h3>
<p>Homologous recombination deficiency (HRD) phenotype will sensitize tumors to poly (ADP-ribose) polymerases inhibitors and platinum. However, previous studies did not focus on the prevalence of HRD among Chinese breast cancer (BC) patients.</p></section><section id="sec2_pmc"><h3 class="pmc_sec_title">Methods</h3>
<p>One hundred and forty-seven BC patients were included in this study. Their HRD status was assessed by Genomic Scar Score (GSS), which was determined according to the length, site, and type of copy number. HRD was defined as positive when a harmful BRCA1/2 mutation was detected or GSS ≥50.</p></section><section id="sec3_pmc"><h3 class="pmc_sec_title">Results</h3>
<p>Our data revealed that 9.5% of the 147 patients tested positive for BRCA1/2 mutation, while approximately 34.7% were HRD-positive. For triple negative BC (TNBC), HRD positivity rate (60.5%) was higher than Luminal A (5.3%), Luminal B (HER2-) (28.8%), and Luminal B (HER2+) (31.6%) subgroups. HRD-positive tumors were more likely to be ER/PR-negative and exhibited higher Ki-67 expression. 50.0% of the HRD-positive patients achieved pathologic complete remission (pCR) after neoadjuvant therapy. HRD-positive patients tended to have a higher risk for cancer recurrence or metastasis compared to HRD-negative patients (29.4% vs. 13.5%).</p></section><section id="sec4_pmc"><h3 class="pmc_sec_title">Conclusion</h3>
<p>We investigated the HRD status among Chinese BC patients using an HRD detection tool developed based on the Chinese population. The clinical characteristics, pathological profile, family history pattern, neoadjuvant efficacy, and disease progression events of HRD-positive and negative patients were described and compared. Thus, our data provided an evidence-based basis for applying the original HRD assay in Chinese BC.</p></section><section id="kwrds0010" class="kwd-group"><p><strong>Keywords:</strong> Breast cancer, BRCA1/2, Homologous recombination deficiency, Genomic scar score, Clinical characteristics</p></section></section><section class="abstract" id="abs0015"><h2>Highlights</h2>
<ul id="ulist0010" class="list" style="list-style-type:none">
<li id="u0010">
<span class="label">•</span><p class="display-inline" id="p0010">GSS-high tumors were more prevalent in TNBC than in Luminal A, Luminal B (HER2-), and Luminal B (HER2+) subtypes.</p>
</li>
<li id="u0015">
<span class="label">•</span><p class="display-inline" id="p0015">HRD-positive tumors were more likely to be ER/PR-negative and exhibited higher Ki-67 expression.</p>
</li>
<li id="u0025">
<span class="label">•</span><p class="display-inline" id="p0025">HRD-positive patients were more likely to suffer from contralateral BC.</p>
</li>
</ul></section><section id="nomen0010"><h2 class="pmc_sec_title">Abbreviations</h2>
<dl class="def-list">
<dt id="d0010">breast cancer</dt>
<dd><p id="p0030">(BC)</p></dd>
<dt id="d0015">chromosomal copy number</dt>
<dd><p id="p0035">(CNV)</p></dd>
<dt id="d0020">estrogen receptor</dt>
<dd><p id="p0040">(ER)</p></dd>
<dt id="d0025">fluorescence in situ hybridization</dt>
<dd><p id="p0045">(FISH)</p></dd>
<dt id="d0030">genomic instability score</dt>
<dd><p id="p0050">(GIS)</p></dd>
<dt id="d0035">genomic scar score</dt>
<dd><p id="p0055">(GSS)</p></dd>
<dt id="d0040">homologous recombination deficiency</dt>
<dd><p id="p0060">(HRD)</p></dd>
<dt id="d0045">homologous recombination repair</dt>
<dd><p id="p0065">(HRR)</p></dd>
<dt id="d0050">human epidermal growth factor receptor 2</dt>
<dd><p id="p0070">(HER2)</p></dd>
<dt id="d0055">immunohistochemical</dt>
<dd><p id="p0075">(IHC)</p></dd>
<dt id="d0060">invasive disease-free survival</dt>
<dd><p id="p0080">(iDFS)</p></dd>
<dt id="d0065">large-scale state transitions</dt>
<dd><p id="p0085">(LST)</p></dd>
<dt id="d0070">length of copy number</dt>
<dd><p id="p0090">(LCN)</p></dd>
<dt id="d0075">loss of heterozygosity</dt>
<dd><p id="p0095">(LOH)</p></dd>
<dt id="d0080">PARP inhibitors</dt>
<dd><p id="p0100">(PARPis)</p></dd>
<dt id="d0085">Poly (ADP-ribose) polymerase proteins</dt>
<dd><p id="p0105">(PARPs)</p></dd>
<dt id="d0090">progesterone receptor</dt>
<dd><p id="p0110">(PR)</p></dd>
<dt id="d0095">progression-free survival</dt>
<dd><p id="p0115">(PFS)</p></dd>
<dt id="d0100">second primary cancer</dt>
<dd><p id="p0120">(SPC)</p></dd>
<dt id="d0105">site of copy number</dt>
<dd><p id="p0125">(SCN)</p></dd>
<dt id="d0110">support vector machine</dt>
<dd><p id="p0130">(SVM)</p></dd>
<dt id="d0115">telomeric allelic imbalances</dt>
<dd><p id="p0135">(TAI)</p></dd>
<dt id="d0120">triple negative BC</dt>
<dd><p id="p0140">(TNBC)</p></dd>
<dt id="d0125">type of copy number</dt>
<dd><p id="p0145">(TCN)</p></dd>
</dl></section><section id="sec1"><h2 class="pmc_sec_title">1. Introduction</h2>
<p id="p0150">Female breast cancer (BC) has surpassed lung cancer as the most commonly diagnosed cancer (11.7% of total cases) worldwide and the leading cause of cancer death in women [<a href="#bib1" class="usa-link" aria-describedby="bib1">1</a>]. In China, breast cancer also ranked first, accounting for 16.7% (306,000) of all new cancer cases in women, and contributed to the most cancer deaths in the younger group (age 15–44 years) [<a href="#bib2" class="usa-link" aria-describedby="bib2">2</a>]. Thus, breast cancer has posed a significant threat to women's health and a considerable disease burden to developing countries, including China. Although globally standardized treatment regimens are accessible, personalized medication targeting individual genetic defects or mutations is considered more effective and promising to improve patients' prognosis. Genomic instability is one of the most critical factors that drive oncogenic transformation and tumorigenesis, and DNA repair deficiency has been described as a hallmark of cancers [<a href="#bib3" class="usa-link" aria-describedby="bib3">3</a>]. Homologous recombination repair (HRR) is a critical DNA repair pathway by which DNA damage, mainly DNA double-strand breaks and interstrand cross-links, can be corrected using the sister chromatid as a template for repair [<a href="#bib4" class="usa-link" aria-describedby="bib4">4</a>]. Additionally, HRR pathways support the recovery of stalled replication forks during DNA replication [<a href="#bib5" class="usa-link" aria-describedby="bib5">5</a>]. Deficiency of the HRR mechanism is termed homologous recombination deficiency (HRD), which has been proven to correlate with carcinogenesis and progression of multiple tumor types. Successful HRR depends on a series of functioning proteins, among which BRCA1 and BRCA2 are the most studied and considered to play critical roles [<a href="#bib6" class="usa-link" aria-describedby="bib6">6</a>]. Any germline or somatic mutations and epigenetic modifications of BRCA1 and BRCA2 could result in an HRD phenotype in cancer, including breast, ovarian, pancreatic, and prostate cancer. Other genes involved in the HRR pathway, such as ATM, PALB2, and RAD51, have also been determined to define an HRD phenotype, though less consistent than BRCA1/2 among various cancers [<a href="#bib7" class="usa-link" aria-describedby="bib7">7</a>]. Thus studies investigating the role of these genes in HRD phenotype between different cancer types are undergoing recently.</p>
<p id="p0155">Based on previous data, HRD was most prevalent in ovarian, breast, prostate, and pancreatic cancer (85% combined) and only occurred sporadically in other cancer types (15%) [<a href="#bib7" class="usa-link" aria-describedby="bib7">7</a>]. As for BC prevalence of germline mutations in BRCA1 and BRCA2 were 7.8% and 5.7%, while the prevalence of somatic mutations in BRCAl and BRCA2 was 3.4% and 2.7%, respectively. Compared to other molecular subtypes of BC, triple negative BC (TNBC) had significantly higher rates of BRCA1 mutations(14.4%) and BRCA2 mutations (3.9%) [<a href="#bib8" class="usa-link" aria-describedby="bib8">8</a>]. The risk of contralateral breast cancer was substantially higher in BRCA1/2 mutation carriers [<a href="#bib9" class="usa-link" aria-describedby="bib9">9</a>]. Therefore, the value of BRCA1/2 mutation testing in BC patients is receiving more attention, and the proportion of genetic screening for BRCA1/2 mutation in BC patients, especially those with a high risk of recurrence, is rapidly increasing in clinical practice.</p>
<p id="p0160">Poly (ADP-ribose) polymerase proteins (PARPs) are nuclear enzymes that participate in the base excision repair process of single-strand DNA repair [<a href="#bib10" class="usa-link" aria-describedby="bib10">10</a>]. PARPs act on sites of single-strand DNA breaks [<a href="#bib11" class="usa-link" aria-describedby="bib11">11</a>]. Once bound to DNA, PARP1 transfers a poly(ADP-ribose) group to itself using nicotinamide adenine dinucleotide in a process called “PARylation” [<a href="#bib12" class="usa-link" aria-describedby="bib12">12</a>]. This PARylation activity helps recruit many DNA damage repair effectors, effectively repairing single-stranded DNA breaks. PARP inhibitors (PARPis) could induce dysfunctional DNA single-strand break repair, converting single-stranded breaks to double-stranded breaks during replication [<a href="#bib13" class="usa-link" aria-describedby="bib13">13</a>]. In cells with BRCA1/2 mutations that cannot repair double-stranded breaks through HRR pathway, the adoption of PARPis leads to synthetic lethality of the cell [<a href="#bib14" class="usa-link" aria-describedby="bib14">14</a>]. PARPis were first approved for ovarian cancer [<a href="#bib15" class="usa-link" aria-describedby="bib15">15</a>]. Subsequently, clinical trials, such as OlympiAD and OlympiA, confirmed that PARPis significantly improved progression-free survival (PFS) in BC with BRCA1/2 mutations. Therefore, the FDA approved PARPis for BC patients with BRCA1/2 mutation [<a href="#bib16" class="usa-link" aria-describedby="bib16">16</a>,<a href="#bib17" class="usa-link" aria-describedby="bib17">17</a>]. However, As mentioned above, besides BRCA1/2 mutations, abnormalities of other non-BRCA genes in the HRR pathway also lead to an HRD phenotype (traits which are collectively referred to as “BRCAness”) [<a href="#bib18" class="usa-link" aria-describedby="bib18">18</a>]. Notably, 50%–60% of TNBC patients are speculated to present as “BRCAness” [<a href="#bib19" class="usa-link" aria-describedby="bib19">19</a>]. Recently, with the advancement of HRD research, HRD-positive patients, including those without BRCA mutations, have benefited from PARPis. The SWOG S1416 study showed improved PFS in the cisplatin plus veliparib group compared to the cisplatin plus placebo treated group in the BRCA-like (BRCA mutation-negative but HRD-positive) population (median PFS of 5.7 months vs. 4.3 months) [<a href="#bib20" class="usa-link" aria-describedby="bib20">20</a>]. GeparSixto indicated that with or without carboplatin, HRD-positive patients were more likely to reach pCR than patients with HR nondeficient tumors [<a href="#bib21" class="usa-link" aria-describedby="bib21">21</a>]. Therefore, accurate screening for patients carrying HRD should be seriously considered beyond mere detection of BRCA1/2 mutation.</p>
<p id="p0165">Until now, there has been no consensus on the gene set that defines HRD and no systematic evaluation of the different methods to determine HRD [<a href="#bib22" class="usa-link" aria-describedby="bib22">22</a>]. However, popular clinical sequencing assays for HRD consist of four categories: HRR-related gene mutation assays [<a href="#bib23" class="usa-link" aria-describedby="bib23">23</a>], genomic scar analysis [<a href="#bib24" class="usa-link" aria-describedby="bib24">24</a>], mutational signatures [<a href="#bib25" class="usa-link" aria-describedby="bib25">25</a>], and HRD functional assays [<a href="#bib26" class="usa-link" aria-describedby="bib26">26</a>]. Two commercial genomic scar assays have been developed, namely the “myChoice HRD test” from Myriad Genetics and the “FoundationOne CDx” assay from Foundation Medicine. The “myChoice HRD test” integrates the loss of heterozygosity (LOH), the number of telomeric allelic imbalances (TAI), and the large-scale state transitions (LST) to evaluate a combined HRD score named Genomic Instability Score (GIS). HRD-positive status is defined as Genomic Instability Score≥42 and/or pathogenic or likely pathogenic mutations in BRCA1/2 [<a href="#bib27" class="usa-link" aria-describedby="bib27">27</a>]. The “FoundationOne CDx” assay evaluates the proportion of LOH fragments in the entire genome. HRD-positive status is defined as patients with tumor tissue BRCA positivity and/or LOH ≥16% [<a href="#bib28" class="usa-link" aria-describedby="bib28">28</a>]. Presently, no HRD test kits evaluating genomic scars based on single nucleotide polymorphism (SNPs) have been approved for BC. The myChoice HRD test is mainly based on genetic data from the Caucasian population [<a href="#bib29" class="usa-link" aria-describedby="bib29">29</a>], and more clinical data is yet required to determine its reliability among Chinese. The FoundationOne CDx was continuously adjusted according to clinical trials, such as platinum REAL2, ARIEL2, and ARIEL3 for rucaparib. By now, ≥16% has been determined as the threshold of the LOH score [<a href="#bib30" class="usa-link" aria-describedby="bib30">30</a>]. However, the applicability of HRD cut-off scores in Chinese populations is still unknown and should be determined based on the association between genomic damage and molecular variants in HRR-associated genes. Therefore, the development and clinical verification of these kits should be promoted urgently.</p>
<p id="p0170">In this study, we revealed the HRD status of Chinese BC patients based on genetic scar scores. We explored the relationship between HRD status and clinical characteristics. In addition, our data provided an evidence-based basis for predicting the efficacy of neoadjuvant chemotherapy in Chinese BC patients who are negative for BRCA 1/2 mutation but positive for HRD status.</p></section><section id="sec2"><h2 class="pmc_sec_title">2. Materials and methods</h2>
<section id="sec2.1"><h3 class="pmc_sec_title">2.1. Patients and samples</h3>
<p id="p0175">This study was approved by the Ethics Committee of the Second Affiliated Hospital of Xi'an Jiaotong University (The approval number: 2022076). One hundred forty-seven patients diagnosed with breast cancer in the Second Affiliated Hospital of Xi'an Jiaotong University were recruited for this study. All patients signed informed consent. Clinical and pathological information, including age, menstrual history, medical history, family history, tumor size, lymph node metastasis, immunohistochemical (IHC) evaluation of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67, was obtained from medical records and pathology reports (<a href="#fig1" class="usa-link">Fig. 1</a>). IHC evaluations were performed in a blinded and independent way by two qualified pathologists. A joint re-assessment would be made for the final consensus. According to The 13th St Gallen International Expert Consensus, the cutoffs for ER and PR were 1% [<a href="#bib31" class="usa-link" aria-describedby="bib31">31</a>]. HER2 status was first determined by IHC. 0 or 1+ was considered HER2 negative, and 3+ was considered positive. In samples showing IHC 2+, fluorescence in situ hybridization (FISH) amplification was applied, as described in a previous study [<a href="#bib32" class="usa-link" aria-describedby="bib32">32</a>].</p>
<figure class="fig xbox font-sm" id="fig1" title="Fig. 1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10165146_gr1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0829/10165146/de52686b9d07/gr1.jpg" loading="lazy" height="368" width="765" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Flow chart of this study.</p></figcaption></figure></section><section id="sec2.2"><h3 class="pmc_sec_title">2.2. Determination of HRD: genomic scar score (GSS)</h3>
<p id="p0180">The formalin fixation and paraffin embedding tumor samples were obtained from a core-needle biopsy before neoadjuvant chemotherapy or from surgically removed tumors of untreated patients. Using HANDLE technology (Halo-shape ANnealing and Defer-Ligation Enrichment System), a modified Molecular Inversion Probe, to construct an amplicon-based DNA library. The tumor cell content for the HRD detection was not less than 30%. HRD Complete panel (Amoydx Ltd., Xiamen, China), covering 1.5 MB of human genomic regions, and including all exons of BRCA1/2 and 24,000 (24 k) target SNPs distributed across the complete human genome [<a href="#bib33" class="usa-link" aria-describedby="bib33">33</a>]. Sequencing was performed by NovaSeq 6000 platform (Illumina, Inc).</p>
<p id="p0185">According to physical or biological properties, each chromosomal copy number (CNV) was divided into three categories, including length of copy number (LCN), site of copy number (SCN), and type of copy number (TCN). LCN consisted of three groups: large (&gt;15 Mb), middle (10–15 Mb), and small (&lt;5 Mb); SCN included telomere, centromere, and other repetitive sequences; TCN consisted of LOH, allele-specific CNV, and allele-balance CNV. These three independent categories of variables were combined to form an entity description for chromosomal copy number. The weight of each entity description item was trained from patients with gBRCA 1/2 deficient and patients with the quiescent genome. Finally, through support vector machine (SVM) training, the weights of entity description items were summed to obtain the Genomic Scar Score (GSS). GSS ≥50 was considered positive for HRD [<a href="#bib33" class="usa-link" aria-describedby="bib33">33</a>].</p>
<p id="p0190">According to a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists [<a href="#bib34" class="usa-link" aria-describedby="bib34">34</a>], HRR pathway genes, including ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and RAD54L, were classified into a 4-tiered system: tier I, variants of vital clinical significance; tier II, variants of potential clinical significance; tier III, variants of unknown significance; and tier IV, variants deemed benign or likely benign. The HRR-positive mutation was defined as tier I or II (<a href="#appsec1" class="usa-link">Supplementary Table 1</a>). HRD-positive was defined by BRCA1/2 mutation-positive or GSS ≥50. If the BRCA1/2 mutation was positive, germline verification was performed using the patient's blood sample.</p></section><section id="sec2.3"><h3 class="pmc_sec_title">2.3. Statistical analysis</h3>
<p id="p0195">Statistical analysis was performed using the R statistical software 4.1.2. The chi-squared test, Fisher's exact test, and Wilcoxon rank sum test were used to identify differences between HRD status and clinical characteristics. A two-sided P value ≤ 0.05 was considered statistically significant.</p></section></section><section id="sec3"><h2 class="pmc_sec_title">3. Results</h2>
<section id="sec3.1"><h3 class="pmc_sec_title">3.1. HRD status based on GSS</h3>
<p id="p0200">Of the 147 patients, 4.1% (6/147) were BRCA1 mutation-positive, including 83.3% (5/6) germline mutations and 16.7% (1/6) somatic mutations. Regarding mutation type, frameshift accounted for 66.7% (4/6) and missense for 33.3% (2/6). 5.4% (8/147) of the patients were BRCA2 mutation-positive (<a href="#fig2" class="usa-link">Fig. 2</a>A), including 87.5% (7/8) frameshift mutations and 12.5% (1/8) missense mutations. All patients with BRCA2 mutations were germline mutations (<a href="#tbl1" class="usa-link">Table 1</a>). According to their BRCA1/2 mutation and GSS, We tested the GSS of all patients and divided them into four subgroups, including (1) BRCA1/2+ &amp; GSS≥50; (2) BRCA1/2- &amp; GSS≥50; (3) BRCA1/2+ &amp; GSS＜50; and (4) BRCA1/2- &amp; GSS＜50 (<a href="#tbl2" class="usa-link">Table 2</a>). According to the definition of HRD, groups (1), (2) and (3) were defined as HRD positive. Approximately 34.7% (51/147) of patients were HRD-positive. Up to 25.2% (37/147) of patients were tested negative for BRCA1/2 mutation but HRD-positive. The HRR mutation rate was 12.9% (19/147), including 84.2% (16/19) HRD-positive and 15.8% (3/19) HRD-negative (<a href="#fig2" class="usa-link">Fig. 2</a>B). The mutation rates of ATM, BRAD1, CHEK2, FANCL, and PLAB2 were all 0.7% (1/147). No HRR-positive mutations were detected in BRIP1, CDK12, CHEK1, RAD51B, RAD51C, RAD51D, or RAD54L. No remaining HRR-positive mutations were found in patients (<a href="#fig2" class="usa-link">Fig. 2</a>C, <a href="#appsec1" class="usa-link">Supplementary Table 2</a>). The rate of TP53 mutations was higher (62.7%) in HRD-positive patients (62.7% vs. 25.0%, P = 7.27*10^-6&lt;0.05) (<a href="#fig2" class="usa-link">Fig. 2</a>D).</p>
<figure class="fig xbox font-sm" id="fig2" title="Fig. 2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10165146_gr2.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0829/10165146/1c6a0a478f98/gr2.jpg" loading="lazy" height="446" width="764" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Homologous recombination deficiency (HRD) positivity distribution in breast cancer (BC) patients. HRD positivity rate in unselected patients (A). Relationship between Homologous recombination repair (HRR) mutations and HRD positivity rate (B). Heatmap of HRR mutations. Tier I: variants of vital clinical significance; Tier II: variants of potential clinical significance; Tier III: variants of unknown significance (C). Relationship between TP53 mutation rate and HRD status (D).</p></figcaption></figure><section class="tw xbox font-sm" id="tbl1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Germline validation in 14 BRCA1/2 mutation-positive patients.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th colspan="1" rowspan="1">No.</th>
<th colspan="1" rowspan="1">Germline/somatic mutation</th>
<th colspan="1" rowspan="1">Gene</th>
<th colspan="1" rowspan="1">Variation</th>
<th colspan="1" rowspan="1">Protein change</th>
<th colspan="1" rowspan="1">Molecular consequence</th>
<th colspan="1" rowspan="1">Classification</th>
<th colspan="1" rowspan="1">Clinical significance</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">Germline</td>
<td align="left" colspan="1" rowspan="1">BRCA2</td>
<td align="left" colspan="1" rowspan="1">c.3847_3848del</td>
<td align="left" colspan="1" rowspan="1">p.V1283Kfs*2</td>
<td align="left" colspan="1" rowspan="1">frameshift</td>
<td align="left" colspan="1" rowspan="1">I</td>
<td align="left" colspan="1" rowspan="1">Pathogenic</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">35</td>
<td align="left" colspan="1" rowspan="1">Germline</td>
<td align="left" colspan="1" rowspan="1">BRCA2</td>
<td align="left" colspan="1" rowspan="1">c.36del</td>
<td align="left" colspan="1" rowspan="1">p.F12Lfs*13</td>
<td align="left" colspan="1" rowspan="1">frameshift</td>
<td align="left" colspan="1" rowspan="1">I</td>
<td align="left" colspan="1" rowspan="1">Pathogenic</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">36</td>
<td align="left" colspan="1" rowspan="1">Somatic</td>
<td align="left" colspan="1" rowspan="1">BRCA1</td>
<td align="left" colspan="1" rowspan="1">c.5470_5477del</td>
<td align="left" colspan="1" rowspan="1">p.I1824Dfs*3</td>
<td align="left" colspan="1" rowspan="1">frameshift</td>
<td align="left" colspan="1" rowspan="1">I</td>
<td align="left" colspan="1" rowspan="1">Pathogenic</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">44</td>
<td align="left" colspan="1" rowspan="1">Germline</td>
<td align="left" colspan="1" rowspan="1">BRCA2</td>
<td align="left" colspan="1" rowspan="1">c.5576_5579del</td>
<td align="left" colspan="1" rowspan="1">p.I1859Kfs*3</td>
<td align="left" colspan="1" rowspan="1">frameshift</td>
<td align="left" colspan="1" rowspan="1">I</td>
<td align="left" colspan="1" rowspan="1">Pathogenic</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">46</td>
<td align="left" colspan="1" rowspan="1">Germline</td>
<td align="left" colspan="1" rowspan="1">BRCA1</td>
<td align="left" colspan="1" rowspan="1">c.5470_5477del</td>
<td align="left" colspan="1" rowspan="1">p.I1824Dfs*3</td>
<td align="left" colspan="1" rowspan="1">frameshift</td>
<td align="left" colspan="1" rowspan="1">I</td>
<td align="left" colspan="1" rowspan="1">Pathogenic</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">61</td>
<td align="left" colspan="1" rowspan="1">Germline</td>
<td align="left" colspan="1" rowspan="1">BRCA2</td>
<td align="left" colspan="1" rowspan="1">c.3319del</td>
<td align="left" colspan="1" rowspan="1">p.Q1107Kfs*12</td>
<td align="left" colspan="1" rowspan="1">frameshift</td>
<td align="left" colspan="1" rowspan="1">I</td>
<td align="left" colspan="1" rowspan="1">Likely Pathogenic</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">70</td>
<td align="left" colspan="1" rowspan="1">Germline</td>
<td align="left" colspan="1" rowspan="1">BRCA2</td>
<td align="left" colspan="1" rowspan="1">c.9285C &gt; A</td>
<td align="left" colspan="1" rowspan="1">p.D3095E</td>
<td align="left" colspan="1" rowspan="1">missense</td>
<td align="left" colspan="1" rowspan="1">I</td>
<td align="left" colspan="1" rowspan="1">Pathogenic</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">73</td>
<td align="left" colspan="1" rowspan="1">Germline</td>
<td align="left" colspan="1" rowspan="1">BRCA1</td>
<td align="left" colspan="1" rowspan="1">c.3869_3870delAA</td>
<td align="left" colspan="1" rowspan="1">p.K1290Mfs*4</td>
<td align="left" colspan="1" rowspan="1">frameshift</td>
<td align="left" colspan="1" rowspan="1">I</td>
<td align="left" colspan="1" rowspan="1">Pathogenic</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">96</td>
<td align="left" colspan="1" rowspan="1">Germline</td>
<td align="left" colspan="1" rowspan="1">BRCA1</td>
<td align="left" colspan="1" rowspan="1">c.981_982del</td>
<td align="left" colspan="1" rowspan="1">p.C328*</td>
<td align="left" colspan="1" rowspan="1">nonsense</td>
<td align="left" colspan="1" rowspan="1">I</td>
<td align="left" colspan="1" rowspan="1">Pathogenic</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">100</td>
<td align="left" colspan="1" rowspan="1">Germline</td>
<td align="left" colspan="1" rowspan="1">BRCA1</td>
<td align="left" colspan="1" rowspan="1">c.5470_5477del</td>
<td align="left" colspan="1" rowspan="1">p.I1824Dfs*3</td>
<td align="left" colspan="1" rowspan="1">frameshift</td>
<td align="left" colspan="1" rowspan="1">I</td>
<td align="left" colspan="1" rowspan="1">Pathogenic</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">110</td>
<td align="left" colspan="1" rowspan="1">Germline</td>
<td align="left" colspan="1" rowspan="1">BRCA2</td>
<td align="left" colspan="1" rowspan="1">c.8537_8538del</td>
<td align="left" colspan="1" rowspan="1">p.E2846Gfs*22</td>
<td align="left" colspan="1" rowspan="1">frameshift</td>
<td align="left" colspan="1" rowspan="1">I</td>
<td align="left" colspan="1" rowspan="1">Pathogenic</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">139</td>
<td align="left" colspan="1" rowspan="1">Germline</td>
<td align="left" colspan="1" rowspan="1">BRCA2</td>
<td align="left" colspan="1" rowspan="1">c.6468_6469del</td>
<td align="left" colspan="1" rowspan="1">p.Q2157Ifs*18</td>
<td align="left" colspan="1" rowspan="1">frameshift</td>
<td align="left" colspan="1" rowspan="1">I</td>
<td align="left" colspan="1" rowspan="1">Pathogenic</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">140</td>
<td align="left" colspan="1" rowspan="1">Germline</td>
<td align="left" colspan="1" rowspan="1">BRCA2</td>
<td align="left" colspan="1" rowspan="1">c.9253dup</td>
<td align="left" colspan="1" rowspan="1">p.T3085Nfs*26</td>
<td align="left" colspan="1" rowspan="1">frameshift</td>
<td align="left" colspan="1" rowspan="1">I</td>
<td align="left" colspan="1" rowspan="1">Pathogenic</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">147</td>
<td align="left" colspan="1" rowspan="1">Germline</td>
<td align="left" colspan="1" rowspan="1">BRCA1</td>
<td align="left" colspan="1" rowspan="1">c.5511G &gt; A</td>
<td align="left" colspan="1" rowspan="1">p.W1837*</td>
<td align="left" colspan="1" rowspan="1">nonsense</td>
<td align="left" colspan="1" rowspan="1">I</td>
<td align="left" colspan="1" rowspan="1">Pathogenic</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tbl1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><section class="tw xbox font-sm" id="tbl2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Subgroups of breast cancer patients according to GSS and BRCA1/2 mutations.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th colspan="1" rowspan="1">Group</th>
<th colspan="1" rowspan="1">BRCA1/2 mutation</th>
<th colspan="1" rowspan="1">GSS</th>
<th colspan="1" rowspan="1">HRD</th>
<th colspan="1" rowspan="1">N(%)</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">(1)</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">≥50</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">13 (8.8%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">(2)</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">≥50</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">37 (25.2%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">(3)</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">＜50</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">1 (0.7%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">(4)</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">＜50</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">96 (65.3%)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tbl2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="sec3.2"><h3 class="pmc_sec_title">3.2. Clinicopathological characteristics of BC patients</h3>
<p id="p0205">The median age of 147 patients was 47.5 (range 17–76) (<a href="#tbl3" class="usa-link">Table 3</a>). One hundred forty-two were invasive carcinomas, and five were carcinomas in situ. The invasive carcinomas were further classified into five molecular subtypes according to the expression of ER, PR, HER2, and Ki67, which were Luminal A (13.4%, 19/142), Luminal B (HER2-) (41.5%, 59/142), Luminal B (HER2+) (13.4%, 19/142), HER2+ (4.9%, 7/142), and TNBC (26.8%, 38/142) (<a href="#fig3" class="usa-link">Fig. 3</a>A). Among patients with TNBC, the HRD positivity rate was 60.5% (23/38), and the BRCA mutation positivity rate was 18.4% (7/38). Moreover, 42.1% (16/38) of patients with TNBC were HRD-positive but tested negative for BRCA mutation (<a href="#tbl3" class="usa-link">Table 3</a>). In the other four subtypes, 26.0% (27/104) of patients tested for HRD-positive, which was much lower than that of patients with TNBC (26.0% VS 60.5% P = 1.35*10<sup>−4</sup>&lt;0.05) (<a href="#tbl3" class="usa-link">Table 3</a>).</p>
<section class="tw xbox font-sm" id="tbl3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Clinical characteristics of breast cancer patients with HRD status.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th rowspan="2" colspan="1">Characteristics</th>
<th rowspan="2" colspan="1">Number of patients (%)</th>
<th rowspan="2" colspan="1">HRD-</th>
<th colspan="3" rowspan="1">HRD+<hr>
</th>
<th rowspan="2" colspan="1">P value</th>
</tr>
<tr>
<th colspan="1" rowspan="1">Overall</th>
<th colspan="1" rowspan="1">BRCA+</th>
<th colspan="1" rowspan="1">BRCA-</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">N</td>
<td align="left" colspan="1" rowspan="1">147</td>
<td align="left" colspan="1" rowspan="1">96 (65.3%)</td>
<td align="left" colspan="1" rowspan="1">51 (34.7%)</td>
<td align="left" colspan="1" rowspan="1">14 (9.5%)</td>
<td align="left" colspan="1" rowspan="1">37 (25.2%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Age, n (%)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.210</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">＜35</td>
<td align="left" colspan="1" rowspan="1">22 (15%)</td>
<td align="left" colspan="1" rowspan="1">18 (81.8%)</td>
<td align="left" colspan="1" rowspan="1">4 (18.2%)</td>
<td align="left" colspan="1" rowspan="1">2 (9.1%)</td>
<td align="left" colspan="1" rowspan="1">2 (9.1%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">35–55</td>
<td align="left" colspan="1" rowspan="1">91 (61.9%)</td>
<td align="left" colspan="1" rowspan="1">57 (62.6%)</td>
<td align="left" colspan="1" rowspan="1">34 (37.4%)</td>
<td align="left" colspan="1" rowspan="1">8 (8.8%)</td>
<td align="left" colspan="1" rowspan="1">26 (28.6%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">＞55</td>
<td align="left" colspan="1" rowspan="1">34 (23.1%)</td>
<td align="left" colspan="1" rowspan="1">21 (61.8%)</td>
<td align="left" colspan="1" rowspan="1">13 (38.2%)</td>
<td align="left" colspan="1" rowspan="1">4 (11.8%)</td>
<td align="left" colspan="1" rowspan="1">9 (26.5%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Family history, n (%)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.121</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">82 (55.8%)</td>
<td align="left" colspan="1" rowspan="1">58 (70.7%)</td>
<td align="left" colspan="1" rowspan="1">24 (29.3%)</td>
<td align="left" colspan="1" rowspan="1">3 (3.7%)</td>
<td align="left" colspan="1" rowspan="1">21 (25.6%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">65 (44.2%)</td>
<td align="left" colspan="1" rowspan="1">38 (58.5%)</td>
<td align="left" colspan="1" rowspan="1">27 (41.5%)</td>
<td align="left" colspan="1" rowspan="1">11 (16.9%)</td>
<td align="left" colspan="1" rowspan="1">16 (24.6%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Family history of four cancer, n (%)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.085</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">123 (83.7%)</td>
<td align="left" colspan="1" rowspan="1">84 (68.3%)</td>
<td align="left" colspan="1" rowspan="1">39 (31.7%)</td>
<td align="left" colspan="1" rowspan="1">7 (5.7%)</td>
<td align="left" colspan="1" rowspan="1">32 (26%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">24 (16.3%)</td>
<td align="left" colspan="1" rowspan="1">12 (50%)</td>
<td align="left" colspan="1" rowspan="1">12 (50%)</td>
<td align="left" colspan="1" rowspan="1">7 (29.2%)</td>
<td align="left" colspan="1" rowspan="1">5 (20.8%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Menopause, n (%)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.858</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">85 (57.8%)</td>
<td align="left" colspan="1" rowspan="1">55 (64.7%)</td>
<td align="left" colspan="1" rowspan="1">30 (35.3%)</td>
<td align="left" colspan="1" rowspan="1">8 (9.4%)</td>
<td align="left" colspan="1" rowspan="1">22 (25.9%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">62 (42.2%)</td>
<td align="left" colspan="1" rowspan="1">41 (66.1%)</td>
<td align="left" colspan="1" rowspan="1">21 (33.9%)</td>
<td align="left" colspan="1" rowspan="1">6 (9.7%)</td>
<td align="left" colspan="1" rowspan="1">15 (24.2%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Neoadjuvant chemotherapy, n (%)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.942</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">109 (74.1%)</td>
<td align="left" colspan="1" rowspan="1">71 (65.1%)</td>
<td align="left" colspan="1" rowspan="1">38 (34.9%)</td>
<td align="left" colspan="1" rowspan="1">12 (11%)</td>
<td align="left" colspan="1" rowspan="1">26 (23.9%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">38 (25.9%)</td>
<td align="left" colspan="1" rowspan="1">25 (65.8%)</td>
<td align="left" colspan="1" rowspan="1">13 (34.2%)</td>
<td align="left" colspan="1" rowspan="1">2 (5.3%)</td>
<td align="left" colspan="1" rowspan="1">11 (28.9%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Side, n (%)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.588</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Left</td>
<td align="left" colspan="1" rowspan="1">88 (59.9%)</td>
<td align="left" colspan="1" rowspan="1">59 (67%)</td>
<td align="left" colspan="1" rowspan="1">29 (33%)</td>
<td align="left" colspan="1" rowspan="1">7 (8%)</td>
<td align="left" colspan="1" rowspan="1">22 (25%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Right</td>
<td align="left" colspan="1" rowspan="1">59 (40.1%)</td>
<td align="left" colspan="1" rowspan="1">37 (62.7%)</td>
<td align="left" colspan="1" rowspan="1">22 (37.3%)</td>
<td align="left" colspan="1" rowspan="1">7 (11.9%)</td>
<td align="left" colspan="1" rowspan="1">15 (25.4%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ER, n (%)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">&lt;0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">(+)</td>
<td align="left" colspan="1" rowspan="1">102 (69.4%)</td>
<td align="left" colspan="1" rowspan="1">77 (75.5%)</td>
<td align="left" colspan="1" rowspan="1">25 (24.5%)</td>
<td align="left" colspan="1" rowspan="1">7 (6.9%)</td>
<td align="left" colspan="1" rowspan="1">18 (17.6%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">(−)</td>
<td align="left" colspan="1" rowspan="1">45 (30.6%)</td>
<td align="left" colspan="1" rowspan="1">19 (42.2%)</td>
<td align="left" colspan="1" rowspan="1">26 (57.8%)</td>
<td align="left" colspan="1" rowspan="1">7 (15.6%)</td>
<td align="left" colspan="1" rowspan="1">19 (42.2%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PR, n (%)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">&lt;0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">(+)</td>
<td align="left" colspan="1" rowspan="1">91 (61.9%)</td>
<td align="left" colspan="1" rowspan="1">69 (75.8%)</td>
<td align="left" colspan="1" rowspan="1">22 (24.2%)</td>
<td align="left" colspan="1" rowspan="1">6 (6.6%)</td>
<td align="left" colspan="1" rowspan="1">16 (17.6%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">(−)</td>
<td align="left" colspan="1" rowspan="1">56 (38.1%)</td>
<td align="left" colspan="1" rowspan="1">27 (48.2%)</td>
<td align="left" colspan="1" rowspan="1">29 (51.8%)</td>
<td align="left" colspan="1" rowspan="1">8 (14.3%)</td>
<td align="left" colspan="1" rowspan="1">21 (37.5%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">HER2, n (%)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.822</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">(+)</td>
<td align="left" colspan="1" rowspan="1">27 (18.6%)</td>
<td align="left" colspan="1" rowspan="1">17 (63%)</td>
<td align="left" colspan="1" rowspan="1">10 (37%)</td>
<td align="left" colspan="1" rowspan="1">1 (3.7%)</td>
<td align="left" colspan="1" rowspan="1">9 (33.3%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">(−)</td>
<td align="left" colspan="1" rowspan="1">118 (81.4%)</td>
<td align="left" colspan="1" rowspan="1">77 (65.3%)</td>
<td align="left" colspan="1" rowspan="1">41 (34.7%)</td>
<td align="left" colspan="1" rowspan="1">13 (11%)</td>
<td align="left" colspan="1" rowspan="1">28 (23.7%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">KI67, n (%)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">&lt;0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">low</td>
<td align="left" colspan="1" rowspan="1">40 (27.2%)</td>
<td align="left" colspan="1" rowspan="1">36 (90%)</td>
<td align="left" colspan="1" rowspan="1">4 (10%)</td>
<td align="left" colspan="1" rowspan="1">2 (5%)</td>
<td align="left" colspan="1" rowspan="1">2 (5%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">high</td>
<td align="left" colspan="1" rowspan="1">107 (72.8%)</td>
<td align="left" colspan="1" rowspan="1">60 (56.1%)</td>
<td align="left" colspan="1" rowspan="1">47 (43.9%)</td>
<td align="left" colspan="1" rowspan="1">12 (11.2%)</td>
<td align="left" colspan="1" rowspan="1">35 (32.7%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Subtypes, n (%)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">&lt;0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Luminal A</td>
<td align="left" colspan="1" rowspan="1">19 (13.4%)</td>
<td align="left" colspan="1" rowspan="1">18 (94.7%)</td>
<td align="left" colspan="1" rowspan="1">1 (5.3%)</td>
<td align="left" colspan="1" rowspan="1">1 (5.3%)</td>
<td align="left" colspan="1" rowspan="1">0 (0%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Luminall B (HER2-)</td>
<td align="left" colspan="1" rowspan="1">59 (41.5%)</td>
<td align="left" colspan="1" rowspan="1">42 (71.2%)</td>
<td align="left" colspan="1" rowspan="1">17 (28.8%)</td>
<td align="left" colspan="1" rowspan="1">5 (8.5%)</td>
<td align="left" colspan="1" rowspan="1">12 (20.3%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Luminal B(HER2+)</td>
<td align="left" colspan="1" rowspan="1">19 (13.4%)</td>
<td align="left" colspan="1" rowspan="1">13 (68.4%)</td>
<td align="left" colspan="1" rowspan="1">6 (31.6%)</td>
<td align="left" colspan="1" rowspan="1">1 (5.3%)</td>
<td align="left" colspan="1" rowspan="1">5 (26.3%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">HER2+</td>
<td align="left" colspan="1" rowspan="1">7 (4.9%)</td>
<td align="left" colspan="1" rowspan="1">4 (57.1%)</td>
<td align="left" colspan="1" rowspan="1">3 (42.9%)</td>
<td align="left" colspan="1" rowspan="1">0 (0%)</td>
<td align="left" colspan="1" rowspan="1">3 (42.9%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TNBC</td>
<td align="left" colspan="1" rowspan="1">38 (26.8%)</td>
<td align="left" colspan="1" rowspan="1">15 (39.5%)</td>
<td align="left" colspan="1" rowspan="1">23 (60.5%)</td>
<td align="left" colspan="1" rowspan="1">7 (18.4%)</td>
<td align="left" colspan="1" rowspan="1">16 (42.1%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">T stage, n (%)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.842</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Tis</td>
<td align="left" colspan="1" rowspan="1">5 (3.4%)</td>
<td align="left" colspan="1" rowspan="1">4 (80%)</td>
<td align="left" colspan="1" rowspan="1">1 (20%)</td>
<td align="left" colspan="1" rowspan="1">0 (0%)</td>
<td align="left" colspan="1" rowspan="1">1 (20%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">T1 (≤2 cm)</td>
<td align="left" colspan="1" rowspan="1">80 (54.4%)</td>
<td align="left" colspan="1" rowspan="1">54 (67.5%)</td>
<td align="left" colspan="1" rowspan="1">26 (32.5%)</td>
<td align="left" colspan="1" rowspan="1">6 (7.5%)</td>
<td align="left" colspan="1" rowspan="1">20 (25%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">T2 (＞2 cm, ＜5 cm)</td>
<td align="left" colspan="1" rowspan="1">51 (34.7%)</td>
<td align="left" colspan="1" rowspan="1">32 (62.7%)</td>
<td align="left" colspan="1" rowspan="1">19 (37.3%)</td>
<td align="left" colspan="1" rowspan="1">6 (11.8%)</td>
<td align="left" colspan="1" rowspan="1">13 (25.5%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">T3 (≥5 cm)</td>
<td align="left" colspan="1" rowspan="1">7 (4.8%)</td>
<td align="left" colspan="1" rowspan="1">4 (57.1%)</td>
<td align="left" colspan="1" rowspan="1">3 (42.9%)</td>
<td align="left" colspan="1" rowspan="1">1 (14.3%)</td>
<td align="left" colspan="1" rowspan="1">2 (28.6%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">T4</td>
<td align="left" colspan="1" rowspan="1">4 (2.7%)</td>
<td align="left" colspan="1" rowspan="1">2 (50%)</td>
<td align="left" colspan="1" rowspan="1">2 (50%)</td>
<td align="left" colspan="1" rowspan="1">1 (25%)</td>
<td align="left" colspan="1" rowspan="1">1 (25%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">N stage, n (%)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.163</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">N0</td>
<td align="left" colspan="1" rowspan="1">76 (51.7%)</td>
<td align="left" colspan="1" rowspan="1">46 (60.5%)</td>
<td align="left" colspan="1" rowspan="1">30 (39.5%)</td>
<td align="left" colspan="1" rowspan="1">9 (11.8%)</td>
<td align="left" colspan="1" rowspan="1">21 (27.6%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">N1</td>
<td align="left" colspan="1" rowspan="1">51 (34.7%)</td>
<td align="left" colspan="1" rowspan="1">36 (70.6%)</td>
<td align="left" colspan="1" rowspan="1">15 (29.4%)</td>
<td align="left" colspan="1" rowspan="1">4 (7.8%)</td>
<td align="left" colspan="1" rowspan="1">11 (21.6%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">N2</td>
<td align="left" colspan="1" rowspan="1">10 (6.8%)</td>
<td align="left" colspan="1" rowspan="1">5 (50%)</td>
<td align="left" colspan="1" rowspan="1">5 (50%)</td>
<td align="left" colspan="1" rowspan="1">0 (0%)</td>
<td align="left" colspan="1" rowspan="1">5 (50%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">N3</td>
<td align="left" colspan="1" rowspan="1">10 (6.8%)</td>
<td align="left" colspan="1" rowspan="1">9 (90%)</td>
<td align="left" colspan="1" rowspan="1">1 (10%)</td>
<td align="left" colspan="1" rowspan="1">1 (10%)</td>
<td align="left" colspan="1" rowspan="1">0 (0%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Progression, n (%)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.020</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">119 (81%)</td>
<td align="left" colspan="1" rowspan="1">83 (69.7%)</td>
<td align="left" colspan="1" rowspan="1">36 (30.3%)</td>
<td align="left" colspan="1" rowspan="1">8 (6.7%)</td>
<td align="left" colspan="1" rowspan="1">28 (23.5%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">28 (19%)</td>
<td align="left" colspan="1" rowspan="1">13 (46.4%)</td>
<td align="left" colspan="1" rowspan="1">15 (53.6%)</td>
<td align="left" colspan="1" rowspan="1">6 (21.4%)</td>
<td align="left" colspan="1" rowspan="1">9 (32.1%)</td>
<td colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tbl3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><figure class="fig xbox font-sm" id="fig3" title="Fig. 3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10165146_gr3.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0829/10165146/4bf9bff76f04/gr3.jpg" loading="lazy" height="481" width="764" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Relationship between genomic scar score (GSS) and subtypes of BC. The frequency of 5 subtypes of BC patients (A). Relationship between GSS and immunohistochemistry(IHC) results (B). GSS according to subtypes of BC (C). Comparison of HRD positivity rates in each subtype (D).</p></figcaption></figure><p id="p0210">We determined the GSS for each patient as described previously. GSS-high tumors were more likely to be ER/PR-negative (P &lt; 0.001) and exhibited significantly higher Ki-67 expression (P &lt; 0.001) than HRD-negative tumors (<a href="#fig3" class="usa-link">Fig. 3</a>B). Subtype analysis revealed that patients with TNBC exhibited higher GSS than Luminal A (P = 2.398 × 10<sup>−7</sup> &lt;0.05), Luminal B (HER2-) (P = 1.294 × 10<sup>−6</sup> &lt;0.05), and Luminal B (HER2+) (P = 0.004 &lt; 0.05). Luminal B (HER2-) (P = 0.001 &lt; 0.05) and Luminal B (HER2+) (P = 0.001 &lt; 0.05) showed higher GSS than luminal A. Significant differences were not detected in HER2+ compared to other subtypes (<a href="#fig3" class="usa-link">Fig. 3</a>C). Moreover, HRD positivity was higher in TNBC (60.5%, 23/38) than in Luminal A (5.3%, 1/19, P = 6.79 × 10<sup>−5</sup>&lt;0.05), Luminal B (HER2-) (28.8%, 17/59, P = 0.002 &lt; 0.05) and Luminal B (HER2+) (31.6%, 6/19, P = 0.039 &lt; 0.05). HRD positivity was not significantly different among Luminal A, Luminal B (HER2-), Luminal B (HER2+), and HER2+ subtypes (<a href="#fig3" class="usa-link">Fig. 3</a>D).</p>
<p id="p0215">All patients were interviewed to determine their family history of cancer (<a href="#appsec1" class="usa-link">Supplementary Table 3</a>). 44.2% (65/147) of the patients had a family history of any cancer reviewed. Only 16.3% (24/147) of patients had a family history of breast, ovarian, pancreatic, or prostate cancer. Among patients with a family history, 41.5% (27/65) were HRD-positive. Among patients without a family history, the HRD positivity rate was 29.3% (24/82). However, the difference was not significant (41.5% vs. 29.3%, P = 0.120). We further analyzed the detailed profile of family history in both groups. In the HRD-positive group, the top 4 cancers were: breast cancer (13.7%), lung cancer (13.7%), esophageal cancer (7.8%), and ovarian cancer (3.9%) (<a href="#fig4" class="usa-link">Fig. 4</a>).</p>
<figure class="fig xbox font-sm" id="fig4" title="Fig. 4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10165146_gr4.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0829/10165146/0a733e2b1b17/gr4.jpg" loading="lazy" height="525" width="688" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Comparison of the distribution of family history among HRD-positive and negative patients.</p></figcaption></figure></section><section id="sec3.3"><h3 class="pmc_sec_title">3.3. Relationship between neoadjuvant chemotherapy efficacy and HRD status</h3>
<p id="p0220">Thirty-eight patients received neoadjuvant chemotherapy (<a href="#fig5" class="usa-link">Fig. 5</a>A). Excluding two patients who had not yet get the operation, 12 were HRD-positive, and 24 were HRD-negative. 50.0% (6/12) of HRD-positive patients achieved pCR, whereas only 8.3% (2/24) of HRD-negative patients achieved pCR (P = 0.009 &lt; 0.05) (<a href="#fig5" class="usa-link">Fig. 5</a>B). Eleven patients received platinum-based neoadjuvant chemotherapy. Excluding one patient who had not yet underwent the operation, 60.0% (3/5) of HRD-positive patients achieved pCR, while none of HRD-negative patients achieved pCR.</p>
<figure class="fig xbox font-sm" id="fig5" title="Fig. 5"><h4 class="obj_head">Fig. 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10165146_gr5.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0829/10165146/15e4e08b21ed/gr5.jpg" loading="lazy" height="238" width="790" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Neoadjuvant chemotherapy for BC. Percentage of platinum-based neoadjuvant chemotherapy (A). Relationship between pathologic complete remission (pCR) rate and HRD status (B).</p></figcaption></figure></section><section id="sec3.4"><h3 class="pmc_sec_title">3.4. The relationship between invasive disease-free survival (iDFS) and HRD status</h3>
<p id="p0225">We recorded the iDFS events of all patients. At the time of last follow-up, invasive diseases occurred in 29.4% (15/51) of the HRD-positive patients (<a href="#fig6" class="usa-link">Fig. 6</a>A). Recorded invasive diseases included contralateral breast cancer (20.0%), ipsilateral recurrences (26.7%), distant metastasis (33.3%), and second primary cancer (SPC) (20.0%). Distant metastases were mainly located in bone (13.3%), followed by contralateral supraclavicular lymph nodes (6.7%), ovary (6.7%), and liver (6.7%). SPC included gastric cancer (6.7%), pancreatic cancer (6.7%), and ovarian cancer (6.7%) (<a href="#fig6" class="usa-link">Fig. 6</a>B). In the HRD-negative patients, disease progression occurred in only 13.5% (13/96) of patients (<a href="#fig6" class="usa-link">Fig. 6</a>A), mostly were distant metastases (77.0%), followed by recurrence (15.3%) and SPC (7.7%). Distant metastases were predominantly occurred in the lung (46.2%), followed by bone (23.1%), and only 7.7% in the liver (<a href="#fig6" class="usa-link">Fig. 6</a>B). HRD-positive patients were more susceptible to disease progression than the HRD-negative ones (29.4% vs. 13.5%, P = 0.02 &lt; 0.05).</p>
<figure class="fig xbox font-sm" id="fig6" title="Fig. 6"><h4 class="obj_head">Fig. 6.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10165146_gr6.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0829/10165146/b6f3e9993b23/gr6.jpg" loading="lazy" height="230" width="764" alt="Fig. 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Disease progression in BC patients. The relationship between disease progression and HRD status (A). Comparison of progression events in HRD-positive with negative patients (B).</p></figcaption></figure></section></section><section id="sec4"><h2 class="pmc_sec_title">4. Discussion</h2>
<p id="p0230">Edwin Cuppen et al.'s pan-cancer analysis revealed that the HRD positivity rate in primary ovarian cancer was higher than in primary BC (52% vs. 24%) [<a href="#bib7" class="usa-link" aria-describedby="bib7">7</a>]. However, since the incidence of BC ranked the first among women worldwide [<a href="#bib35" class="usa-link" aria-describedby="bib35">35</a>] and also in China, HRD status in BC should be seriously evaluated in clinical practice. The <a href="https://clinicaltrials.gov/ct2/show/NCT01372579" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01372579</a> study indicated that HRD status could predict pCR rates for neoadjuvant therapy in BC [<a href="#bib36" class="usa-link" aria-describedby="bib36">36</a>]. The PrECOG 0105 study showed that HRD-positive BC patients could benefit greatly from PARPis than HRD-negative patients [<a href="#bib37" class="usa-link" aria-describedby="bib37">37</a>], indicating that assessment for HRD status is necessary for personalized therapy. However, currently, FDA-approved HRD tests are only available for ovarian cancer, and the study population is limited to European-American populations. In China, no HRD test for BC has been officially approved yet. However, efforts have been made to develop accurate and adaptable HRD tests for BC in the Chinese population. In this study, we introduced an original HRD test system, namely AmoyDx HRD Panel based on GSS, and provided clinical data concerning HRD status in BC patients in China.</p>
<p id="p0235">GSS was developed by a machine learning method called the genomic scar (GS) model, which use different types of chromosomal copy number to evaluate genomic instability to predict HRD event [<a href="#bib33" class="usa-link" aria-describedby="bib33">33</a>]. GSS applied in this HRD test shares two prominent advantages. First, SNPs included in the test are specifically selected from the Chinese population. Second, the division of genomic instability events is more precise. Each CNV type was calculated only once, which would help to avoid redundant information. Tim French et al. showed a good agreement between the GSS-based AmoyDx HRD Panel and the myChoice HRD test. The positive, negative, and overall percent concordance between AmoyDx HRD Panel and Myriad myChoice CDx was 88.0%, 75.0%, and 81.6%, respectively [<a href="#bib38" class="usa-link" aria-describedby="bib38">38</a>]. Noteworthy, the development of the model incorporated data from breast and ovarian cancers. However, the predictive power of GS models in the clinic has only been evaluated in patients with ovarian cancer [<a href="#bib33" class="usa-link" aria-describedby="bib33">33</a>]. Our study on breast cancer patients filled this gap.</p>
<p id="p0240">We first explored the relationship between BRCA1/2 mutations, HRR mutations, and HRD positivity rates. This study's BRCA1/2 mutation positivity rate was higher than that reported by Yuntao Xie (9.5% vs. 5.3%) [<a href="#bib39" class="usa-link" aria-describedby="bib39">39</a>]. 25.2% of patients were BRCA1/2 mutation negative but HRD positive, indicating that detection of BRCA1/2 mutations alone would miss a large portion of BC patients who may also benefit from PARP inhibitors. Notably, this BRCA1/2 mutation-negative but HRD-positive rate was much higher in TNBC (42.1%). Then we assessed HRR mutations according to O'Shaughnessy J's study and compared the results with our HRD tests [<a href="#bib40" class="usa-link" aria-describedby="bib40">40</a>]. The results showed that HRR mutation was also not consistent or incompatible with HRD. In fact, the rate of HRR mutation positivity was much lower than HRD positivity rate (12.9% vs. 34.7%). Therefore, it is insufficient to detect only BRCA1/2 or HRR mutations in clinical practice to identify patients that were deficient in homologous recombination repair and those who could use PARPis as effective target therapy. Assessment of HRD based on GSS needs to be taken seriously and be further generalized in the clinical setting.</p>
<p id="p0245">We also investigated the relationship between GSS and the clinicopathological characteristics of BC. The results of subtype analysis revealed that GSS-high tumors were significantly more prevalent in TNBC than in Luminal A, Luminal B (HER2-), and Luminal B (HER2+) subtypes, which is consistent with previous reports [<a href="#bib29" class="usa-link" aria-describedby="bib29">29</a>,<a href="#bib41" class="usa-link" aria-describedby="bib41">41</a>]. Moreover, HRD positivity rate in TNBC (60.5%) was higher than that in unselected BC (34.7%). This tendency is consistent with Imanishi, S's results (51.4% vs. 31.9%) [<a href="#bib42" class="usa-link" aria-describedby="bib42">42</a>]. TNBC subtype shares characteristics including higher recurrence risk and worse prognosis, with limited therapeutic options to choose compared to the hormone receptor-positive and HER-2 positive subtypes. Thus, HRD test should be performed routinely, especially for TNBC patients, to provide them with more therapy options.</p>
<p id="p0250">It is estimated that hereditary BC accounts for 5–10% of all BC. However, about 70% of hereditary BC are not associated with BRCA1/2 mutations [<a href="#bib43" class="usa-link" aria-describedby="bib43">43</a>], indicating that other genes may also play critical roles in the homologous recombination repair pathway [<a href="#bib44" class="usa-link" aria-describedby="bib44">44</a>]. We explored the relationship between HRD and a family history of certain cancers. Patients with a family history of any cancer reviewed are more likely to be HRD-positive (41.5%) than those without a family history (29.3%). However, the difference was not statistically significant. We consider there are two reasons: the relatively small sample size and follow-up limitations. Patients with BRCA1/2 mutation have a high risk of breast cancer, ovarian cancer, prostate cancer, and gastric cancer [<a href="#bib45" class="usa-link" aria-describedby="bib45">45</a>]. Interestingly, we found that relatives of HRD-positive patients were more likely to have a family history of breast cancer, esophageal cancer, and ovarian cancer. Reports concerning this data is rare and we will continue to follow up on these patients in our subsequent study.</p>
<p id="p0255">Recently many studies have suggested the predictive or prognostic value of HRD status for cancers. For example, HRD-positive BC patients can benefit from PARP inhibitors [<a href="#bib20" class="usa-link" aria-describedby="bib20">20</a>], and HRD status could predict the efficacy of platinum-based neoadjuvant chemotherapy [<a href="#bib36" class="usa-link" aria-describedby="bib36">36</a>]. HRD status was also proved to be associated with the outcome of neoadjuvant therapy without addition of platinum [<a href="#bib46" class="usa-link" aria-describedby="bib46">46</a>]. In this study, we found that the pCR rate after neoadjuvant chemotherapy was higher in HRD-positive group compared to HRD-negative group (50% vs. 8.3%), which was consistent with GeparSixto study (55.9% vs. 29.8%) [<a href="#bib46" class="usa-link" aria-describedby="bib46">46</a>]. The efficacy of platinum-based neoadjuvant chemotherapy was superior in HRD-positive patients than that in HRD-negative patients. Although the sample size was too small for statistical analysis, the results are similar to other studies, such as the <a href="https://clinicaltrials.gov/ct2/show/NCT01372579" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01372579</a> [<a href="#bib36" class="usa-link" aria-describedby="bib36">36</a>]. In survival analysis, we found that HRD-positive patients were more likely to suffer from contralateral BC. Previous studies have shown that germline variant carriers were more likely to have contralateral breast cancer (11.5% vs. 2.9%) [<a href="#bib47" class="usa-link" aria-describedby="bib47">47</a>]. However, the necessity and determinants of contralateral prophylactic mastectomy have been controversial. Fasano GA et al. demonstrate that TNBC patients without BRCA1/2 mutations had no survival benefit after contralateral prophylactic mastectomy [<a href="#bib48" class="usa-link" aria-describedby="bib48">48</a>]. At present, no other studies have reported an association between HRD status and the risk of contralateral BC. Therefore, an update of the survival and disease development data of these HRD-positive BC patients is warranted to provide a robust reference for clinicians' choices. Additionally, longer follow-ups will be conducted to achieve satisfactory survival results. We also show that distant metastases of HRD-positive BC were predominantly occurred in the lung (46.2%), followed by bone (23.1%), of which the underlying mechanisms are to be revealed.</p></section><section id="sec5"><h2 class="pmc_sec_title">5. Conclusions</h2>
<p id="p0260">In conclusion, we first investigated the HRD status of the Chinese BC patients through an original HRD detection panel developed based on Chinese population. In addition, the clinicopathological characteristics, family history distribution, neoadjuvant efficacy, and disease progression of HRD-positive and negative patients were described and compared. Our data confirmed the feasibility and reliability of this novel HRD assessment system and suggested that more BC patients, especially TNBC subtype, should undergo HRD screening for sufficient assessment and better therapy options.</p></section><section id="sec6"><h2 class="pmc_sec_title">Author contributions</h2>
<p id="p0265">Conceptualization, Cong Feng, Yinbin Zhang and Fei Wu; Data curation, Cong Feng and Qinghua Tan; Formal analysis, Weiwei Wang; Funding acquisition, Xingcong Ma and Shuqun Zhang; Investigation, Fei Wu; Methodology, Cong Feng, Yinbin Zhang and Xiaoyu Xue; Software, Wei Lv; Supervision, Shuqun Zhang; Validation, Chaofan Li and Xingcong Ma; Visualization, Jia Li and Mengjie Liu; Writing – original draft, Cong Feng; Writing – review &amp; editing, Cong Feng.</p></section><section id="sec7"><h2 class="pmc_sec_title">Funding</h2>
<p id="p0270">This work was supported by National Natural Science Foundation of China (Grant Number: 82003047, 82174164), the Fundamental Research Funds for the Central Universities (Grant Number: xzy012020061), and the funding from the Second Affiliated Hospital of Xi'an Jiaotong University (Grant Number: 2020 YJ(ZYTS)381).</p></section><section id="sec8"><h2 class="pmc_sec_title">Institutional review board statement</h2>
<p id="p0275">The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the Second Affiliated Hospital of Xi'an Jiaotong University (The approval number: 2022076).</p></section><section id="sec9"><h2 class="pmc_sec_title">Informed consent statement</h2>
<p id="p0280">Informed consent was obtained from all subjects involved in the study.</p></section><section id="sec22"><h2 class="pmc_sec_title">Declaration of competing interest</h2>
<p id="p0285">The authors declare no conflict of interest.</p></section><section id="ack0010" class="ack"><h2 class="pmc_sec_title">Acknowledgment</h2>
<p id="p0290">This work is supported by Amoy Diagnostics Co., Ltd.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="d35e1126">
<sup>☆</sup><p class="display-inline" id="ntpara0010">These authors contributed equally to this work.</p>
</div>
<div class="fn p" id="appsec2">
<sup>Appendix A</sup><p class="display-inline" id="p0300">Supplementary data to this article can be found online at <a href="https://doi.org/10.1016/j.breast.2023.04.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.breast.2023.04.002</a>.</p>
</div>
</div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Xingcong Ma, Email: cameo1190@163.com.</p>
<p>Shuqun Zhang, Email: shuqun_zhang1971@163.com.</p></section><section id="appsec1"><h2 class="pmc_sec_title">Appendix A. Supplementary data</h2>
<p id="p0295">The following are the Supplementary data to this article:</p>
<section class="sm xbox font-sm" id="mmc1"><div class="caption p"><span>Multimedia component 1</span></div>
<div class="media p" title="Multimedia component 1"><div class="caption">
<a href="/articles/instance/10165146/bin/mmc1.docx" data-ga-action="click_feat_suppl" class="usa-link">mmc1.docx</a><sup> (17.6KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="mmc2"><div class="caption p"><span>Multimedia component 2</span></div>
<div class="media p" title="Multimedia component 2"><div class="caption">
<a href="/articles/instance/10165146/bin/mmc2.docx" data-ga-action="click_feat_suppl" class="usa-link">mmc2.docx</a><sup> (44.3KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="mmc3"><div class="caption p"><span>Multimedia component 3</span></div>
<div class="media p" title="Multimedia component 3"><div class="caption">
<a href="/articles/instance/10165146/bin/mmc3.xlsx" data-ga-action="click_feat_suppl" class="usa-link">mmc3.xlsx</a><sup> (28.4KB, xlsx) </sup>
</div></div></section></section><section id="cebib0010" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="cebib0010_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="bib1">
<span class="label">1.</span><cite>Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660.</cite> [<a href="https://doi.org/10.3322/caac.21660" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33538338/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=CA%20Cancer%20J%20Clin&amp;title=Global%20cancer%20statistics%202020:%20GLOBOCAN%20estimates%20of%20incidence%20and%20mortality%20worldwide%20for%2036%20cancers%20in%20185%20countries&amp;author=H.%20Sung&amp;author=J.%20Ferlay&amp;author=R.L.%20Siegel&amp;author=M.%20Laversanne&amp;author=I.%20Soerjomataram&amp;volume=71&amp;issue=3&amp;publication_year=2021&amp;pages=209-249&amp;pmid=33538338&amp;doi=10.3322/caac.21660&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib2">
<span class="label">2.</span><cite>Zheng R., Zhang S., Zeng H., Wang S., Sun K., Chen R., Li L., Wei W., He J. Cancer incidence and mortality in China, 2016. J Nat Canc Center. 2022;2(1):1–9. doi: 10.1016/j.jncc.2022.02.002.</cite> [<a href="https://doi.org/10.1016/j.jncc.2022.02.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11256658/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39035212/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Nat%20Canc%20Center&amp;title=Cancer%20incidence%20and%20mortality%20in%20China,%202016&amp;author=R.%20Zheng&amp;author=S.%20Zhang&amp;author=H.%20Zeng&amp;author=S.%20Wang&amp;author=K.%20Sun&amp;volume=2&amp;issue=1&amp;publication_year=2022&amp;pages=1-9&amp;pmid=39035212&amp;doi=10.1016/j.jncc.2022.02.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib3">
<span class="label">3.</span><cite>Ma J., Setton J., Lee N.Y., Riaz N., Powell S.N. The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. Nat Commun. 2018;9(1):3292. doi: 10.1038/s41467-018-05228-y.</cite> [<a href="https://doi.org/10.1038/s41467-018-05228-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6098043/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30120226/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=The%20therapeutic%20significance%20of%20mutational%20signatures%20from%20DNA%20repair%20deficiency%20in%20cancer&amp;author=J.%20Ma&amp;author=J.%20Setton&amp;author=N.Y.%20Lee&amp;author=N.%20Riaz&amp;author=S.N.%20Powell&amp;volume=9&amp;issue=1&amp;publication_year=2018&amp;pages=3292&amp;pmid=30120226&amp;doi=10.1038/s41467-018-05228-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib4">
<span class="label">4.</span><cite>Ciccia A., Elledge S.J. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40(2):179–204. doi: 10.1016/j.molcel.2010.09.019.</cite> [<a href="https://doi.org/10.1016/j.molcel.2010.09.019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2988877/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20965415/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Cell&amp;title=The%20DNA%20damage%20response:%20making%20it%20safe%20to%20play%20with%20knives&amp;author=A.%20Ciccia&amp;author=S.J.%20Elledge&amp;volume=40&amp;issue=2&amp;publication_year=2010&amp;pages=179-204&amp;pmid=20965415&amp;doi=10.1016/j.molcel.2010.09.019&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib5">
<span class="label">5.</span><cite>Li X., Heyer W.D. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 2008;18(1):99–113. doi: 10.1038/cr.2008.1.</cite> [<a href="https://doi.org/10.1038/cr.2008.1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3087377/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18166982/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Res&amp;title=Homologous%20recombination%20in%20DNA%20repair%20and%20DNA%20damage%20tolerance&amp;author=X.%20Li&amp;author=W.D.%20Heyer&amp;volume=18&amp;issue=1&amp;publication_year=2008&amp;pages=99-113&amp;pmid=18166982&amp;doi=10.1038/cr.2008.1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib6">
<span class="label">6.</span><cite>Stewart M.D., Merino Vega D., Arend R.C., Baden J.F., Barbash O., Beaubier N., Collins G., French T., Ghahramani N., Hinson P., et al.  Homologous recombination deficiency: concepts, definitions, and assays. Oncol. 2022;27(3):167–174. doi: 10.1093/oncolo/oyab053.</cite> [<a href="https://doi.org/10.1093/oncolo/oyab053" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8914493/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35274707/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncol&amp;title=Homologous%20recombination%20deficiency:%20concepts,%20definitions,%20and%20assays&amp;author=M.D.%20Stewart&amp;author=D.%20Merino%20Vega&amp;author=R.C.%20Arend&amp;author=J.F.%20Baden&amp;author=O.%20Barbash&amp;volume=27&amp;issue=3&amp;publication_year=2022&amp;pages=167-174&amp;pmid=35274707&amp;doi=10.1093/oncolo/oyab053&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib7">
<span class="label">7.</span><cite>Nguyen L., J W.M.M., Van Hoeck A., Cuppen E. Pan-cancer landscape of homologous recombination deficiency. Nat Commun. 2020;11(1):5584. doi: 10.1038/s41467-020-19406-4.</cite> [<a href="https://doi.org/10.1038/s41467-020-19406-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7643118/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33149131/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=Pan-cancer%20landscape%20of%20homologous%20recombination%20deficiency&amp;author=L.%20Nguyen&amp;author=W.M.M.%20J&amp;author=A.%20Van%20Hoeck&amp;author=E.%20Cuppen&amp;volume=11&amp;issue=1&amp;publication_year=2020&amp;pages=5584&amp;pmid=33149131&amp;doi=10.1038/s41467-020-19406-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib8">
<span class="label">8.</span><cite>Shao C., Wan J., Lam F.C., Tang H., Marley A.R., Song Y., Miller C., Brown M., Han J., Adeboyeje G. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies. Environ Mol Mutagen. 2022;63(6):308–316. doi: 10.1002/em.22505.</cite> [<a href="https://doi.org/10.1002/em.22505" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36054589/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Environ%20Mol%20Mutagen&amp;title=A%20comprehensive%20literature%20review%20and%20meta-analysis%20of%20the%20prevalence%20of%20pan-cancer%20BRCA%20mutations,%20homologous%20recombination%20repair%20gene%20mutations,%20and%20homologous%20recombination%20deficiencies&amp;author=C.%20Shao&amp;author=J.%20Wan&amp;author=F.C.%20Lam&amp;author=H.%20Tang&amp;author=A.R.%20Marley&amp;volume=63&amp;issue=6&amp;publication_year=2022&amp;pages=308-316&amp;pmid=36054589&amp;doi=10.1002/em.22505&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib9">
<span class="label">9.</span><cite>Su L., Xu Y., Ouyang T., Li J., Wang T., Fan Z., Fan T., Lin B., Xie Y. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients. Int J Cancer. 2020;146(12):3335–3342. doi: 10.1002/ijc.32918.</cite> [<a href="https://doi.org/10.1002/ijc.32918" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32037537/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Cancer&amp;title=Contralateral%20breast%20cancer%20risk%20in%20BRCA1%20and%20BRCA2%20mutation%20carriers%20in%20a%20large%20cohort%20of%20unselected%20Chinese%20breast%20cancer%20patients&amp;author=L.%20Su&amp;author=Y.%20Xu&amp;author=T.%20Ouyang&amp;author=J.%20Li&amp;author=T.%20Wang&amp;volume=146&amp;issue=12&amp;publication_year=2020&amp;pages=3335-3342&amp;pmid=32037537&amp;doi=10.1002/ijc.32918&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib10">
<span class="label">10.</span><cite>Hussain M., Daignault-Newton S., Twardowski P.W., Albany C., Stein M.N., Kunju L.P., Siddiqui J., Wu Y.M., Robinson D., Lonigro R.J., et al.  Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012. J Clin Oncol. 2018;36(10):991–999. doi: 10.1200/JCO.2017.75.7310.</cite> [<a href="https://doi.org/10.1200/JCO.2017.75.7310" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6075827/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29261439/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Targeting%20androgen%20receptor%20and%20DNA%20repair%20in%20metastatic%20castration-resistant%20prostate%20cancer:%20results%20from%20NCI%209012&amp;author=M.%20Hussain&amp;author=S.%20Daignault-Newton&amp;author=P.W.%20Twardowski&amp;author=C.%20Albany&amp;author=M.N.%20Stein&amp;volume=36&amp;issue=10&amp;publication_year=2018&amp;pages=991-999&amp;pmid=29261439&amp;doi=10.1200/JCO.2017.75.7310&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib11">
<span class="label">11.</span><cite>Chan D.A., Giaccia A.J. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov. 2011;10(5):351–364. doi: 10.1038/nrd3374.</cite> [<a href="https://doi.org/10.1038/nrd3374" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3652585/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21532565/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Drug%20Discov&amp;title=Harnessing%20synthetic%20lethal%20interactions%20in%20anticancer%20drug%20discovery&amp;author=D.A.%20Chan&amp;author=A.J.%20Giaccia&amp;volume=10&amp;issue=5&amp;publication_year=2011&amp;pages=351-364&amp;pmid=21532565&amp;doi=10.1038/nrd3374&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib12">
<span class="label">12.</span><cite>Ray Chaudhuri A., Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18(10):610–621. doi: 10.1038/nrm.2017.53.</cite> [<a href="https://doi.org/10.1038/nrm.2017.53" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6591728/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28676700/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Mol%20Cell%20Biol&amp;title=The%20multifaceted%20roles%20of%20PARP1%20in%20DNA%20repair%20and%20chromatin%20remodelling&amp;author=A.%20Ray%20Chaudhuri&amp;author=A.%20Nussenzweig&amp;volume=18&amp;issue=10&amp;publication_year=2017&amp;pages=610-621&amp;pmid=28676700&amp;doi=10.1038/nrm.2017.53&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib13">
<span class="label">13.</span><cite>Concannon K., Morris B.B., Gay C.M., Byers L.A. Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. Mol Cell. 2023 doi: 10.1016/j.molcel.2022.12.031.</cite> [<a href="https://doi.org/10.1016/j.molcel.2022.12.031" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9992136/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36669489/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Cell&amp;title=Combining%20targeted%20DNA%20repair%20inhibition%20and%20immune-oncology%20approaches%20for%20enhanced%20tumor%20control&amp;author=K.%20Concannon&amp;author=B.B.%20Morris&amp;author=C.M.%20Gay&amp;author=L.A.%20Byers&amp;publication_year=2023&amp;pmid=36669489&amp;doi=10.1016/j.molcel.2022.12.031&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib14">
<span class="label">14.</span><cite>Saner F.A.M., Herschtal A., Nelson B.H., deFazio A., Goode E.L., Ramus S.J., Pandey A., Beach J.A., Fereday S., Berchuck A., et al.  Going to extremes: determinants of extraordinary response and survival in patients with cancer. Nat Rev Cancer. 2019;19(6):339–348. doi: 10.1038/s41568-019-0145-5.</cite> [<a href="https://doi.org/10.1038/s41568-019-0145-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7255796/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31076661/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Cancer&amp;title=Going%20to%20extremes:%20determinants%20of%20extraordinary%20response%20and%20survival%20in%20patients%20with%20cancer&amp;author=F.A.M.%20Saner&amp;author=A.%20Herschtal&amp;author=B.H.%20Nelson&amp;author=A.%20deFazio&amp;author=E.L.%20Goode&amp;volume=19&amp;issue=6&amp;publication_year=2019&amp;pages=339-348&amp;pmid=31076661&amp;doi=10.1038/s41568-019-0145-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib15">
<span class="label">15.</span><cite>Washington C.R., Moore K.N. Resistance to poly (ADP-Ribose) polymerase inhibitors (PARPi): mechanisms and potential to reverse. Curr Oncol Rep. 2022;24(12):1685–1693. doi: 10.1007/s11912-022-01337-6.</cite> [<a href="https://doi.org/10.1007/s11912-022-01337-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36346509/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Oncol%20Rep&amp;title=Resistance%20to%20poly%20(ADP-Ribose)%20polymerase%20inhibitors%20(PARPi):%20mechanisms%20and%20potential%20to%20reverse&amp;author=C.R.%20Washington&amp;author=K.N.%20Moore&amp;volume=24&amp;issue=12&amp;publication_year=2022&amp;pages=1685-1693&amp;pmid=36346509&amp;doi=10.1007/s11912-022-01337-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib16">
<span class="label">16.</span><cite>Robson M., Im S.A., Senkus E., Xu B., Domchek S.M., Masuda N., Delaloge S., Li W., Tung N., Armstrong A., et al.  Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–533. doi: 10.1056/NEJMoa1706450.</cite> [<a href="https://doi.org/10.1056/NEJMoa1706450" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28578601/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Olaparib%20for%20metastatic%20breast%20cancer%20in%20patients%20with%20a%20germline%20BRCA%20mutation&amp;author=M.%20Robson&amp;author=S.A.%20Im&amp;author=E.%20Senkus&amp;author=B.%20Xu&amp;author=S.M.%20Domchek&amp;volume=377&amp;issue=6&amp;publication_year=2017&amp;pages=523-533&amp;pmid=28578601&amp;doi=10.1056/NEJMoa1706450&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib17">
<span class="label">17.</span><cite>Tutt A.N.J., Garber J.E., Kaufman B., Viale G., Fumagalli D., Rastogi P., Gelber R.D., de Azambuja E., Fielding A., Balmana J., et al.  Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394–2405. doi: 10.1056/NEJMoa2105215.</cite> [<a href="https://doi.org/10.1056/NEJMoa2105215" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9126186/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34081848/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Adjuvant%20olaparib%20for%20patients%20with%20BRCA1-%20or%20BRCA2-mutated%20breast%20cancer&amp;author=A.N.J.%20Tutt&amp;author=J.E.%20Garber&amp;author=B.%20Kaufman&amp;author=G.%20Viale&amp;author=D.%20Fumagalli&amp;volume=384&amp;issue=25&amp;publication_year=2021&amp;pages=2394-2405&amp;pmid=34081848&amp;doi=10.1056/NEJMoa2105215&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib18">
<span class="label">18.</span><cite>Zhang D., Baldwin P., Leal A.S., Carapellucci S., Sridhar S., Liby K.T. A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice. Theranostics. 2019;9(21):6224–6238. doi: 10.7150/thno.36281.</cite> [<a href="https://doi.org/10.7150/thno.36281" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6735511/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31534547/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Theranostics&amp;title=A%20nano-liposome%20formulation%20of%20the%20PARP%20inhibitor%20Talazoparib%20enhances%20treatment%20efficacy%20and%20modulates%20immune%20cell%20populations%20in%20mammary%20tumors%20of%20BRCA-deficient%20mice&amp;author=D.%20Zhang&amp;author=P.%20Baldwin&amp;author=A.S.%20Leal&amp;author=S.%20Carapellucci&amp;author=S.%20Sridhar&amp;volume=9&amp;issue=21&amp;publication_year=2019&amp;pages=6224-6238&amp;pmid=31534547&amp;doi=10.7150/thno.36281&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib19">
<span class="label">19.</span><cite>Rodler E.T., Kurland B.F., Griffin M., Gralow J.R., Porter P., Yeh R.F., Gadi V.K., Guenthoer J., Beumer J.H., Korde L., et al.  Phase I study of veliparib (ABT-888) combined with cisplatin and vinorelbine in advanced triple-negative breast cancer and/or BRCA mutation-associated breast cancer. Clin Cancer Res. 2016;22(12):2855–2864. doi: 10.1158/1078-0432.CCR-15-2137.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-15-2137" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4911292/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26801247/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Phase%20I%20study%20of%20veliparib%20(ABT-888)%20combined%20with%20cisplatin%20and%20vinorelbine%20in%20advanced%20triple-negative%20breast%20cancer%20and/or%20BRCA%20mutation-associated%20breast%20cancer&amp;author=E.T.%20Rodler&amp;author=B.F.%20Kurland&amp;author=M.%20Griffin&amp;author=J.R.%20Gralow&amp;author=P.%20Porter&amp;volume=22&amp;issue=12&amp;publication_year=2016&amp;pages=2855-2864&amp;pmid=26801247&amp;doi=10.1158/1078-0432.CCR-15-2137&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib20">
<span class="label">20.</span><cite>Sharma P., Rodler E., Barlow W.E., Gralow J., Huggins-Puhalla S.L., Anders C.K., Goldstein L.J., Brown-Glaberman U.A., Huynh T.-T., Szyarto C.S., et al.  Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416) J Clin Oncol. 2020;38(15_suppl):1001. doi: 10.1200/JCO.2020.38.15_suppl.1001.</cite> [<a href="https://doi.org/10.1200/JCO.2020.38.15_suppl.1001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Results%20of%20a%20phase%20II%20randomized%20trial%20of%20cisplatin%20+/-%20veliparib%20in%20metastatic%20triple-negative%20breast%20cancer%20(TNBC)%20and/or%20germline%20BRCA-associated%20breast%20cancer%20(SWOG%20S1416)&amp;author=P.%20Sharma&amp;author=E.%20Rodler&amp;author=W.E.%20Barlow&amp;author=J.%20Gralow&amp;author=S.L.%20Huggins-Puhalla&amp;volume=38&amp;issue=15_suppl&amp;publication_year=2020&amp;pages=1001&amp;doi=10.1200/JCO.2020.38.15_suppl.1001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib21">
<span class="label">21.</span><cite>Loibl S., Weber K.E., Timms K.M., Elkin E.P., Hahnen E., Fasching P.A., Lederer B., Denkert C., Schneeweiss A., Braun S., et al.  Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol. 2018;29(12):2341–2347. doi: 10.1093/annonc/mdy460.</cite> [<a href="https://doi.org/10.1093/annonc/mdy460" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30335131/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=Survival%20analysis%20of%20carboplatin%20added%20to%20an%20anthracycline/taxane-based%20neoadjuvant%20chemotherapy%20and%20HRD%20score%20as%20predictor%20of%20response-final%20results%20from%20GeparSixto&amp;author=S.%20Loibl&amp;author=K.E.%20Weber&amp;author=K.M.%20Timms&amp;author=E.P.%20Elkin&amp;author=E.%20Hahnen&amp;volume=29&amp;issue=12&amp;publication_year=2018&amp;pages=2341-2347&amp;pmid=30335131&amp;doi=10.1093/annonc/mdy460&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib22">
<span class="label">22.</span><cite>Park W., Chen J., Chou J.F., Varghese A.M., Yu K.H., Wong W., Capanu M., Balachandran V., McIntyre C.A., El Dika I., et al.  Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection. Clin Cancer Res. 2020;26(13):3239–3247. doi: 10.1158/1078-0432.CCR-20-0418.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-20-0418" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7380542/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32444418/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Genomic%20methods%20identify%20homologous%20recombination%20deficiency%20in%20pancreas%20adenocarcinoma%20and%20optimize%20treatment%20selection&amp;author=W.%20Park&amp;author=J.%20Chen&amp;author=J.F.%20Chou&amp;author=A.M.%20Varghese&amp;author=K.H.%20Yu&amp;volume=26&amp;issue=13&amp;publication_year=2020&amp;pages=3239-3247&amp;pmid=32444418&amp;doi=10.1158/1078-0432.CCR-20-0418&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib23">
<span class="label">23.</span><cite>Sherill-Rofe D., Rahat D., Findlay S., Mellul A., Guberman I., Braun M., Bloch I., Lalezari A., Samiei A., Sadreyev R., et al.  Mapping global and local coevolution across 600 species to identify novel homologous recombination repair genes. Genome Res. 2019;29(3):439–448. doi: 10.1101/gr.241414.118.</cite> [<a href="https://doi.org/10.1101/gr.241414.118" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6396423/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30718334/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genome%20Res&amp;title=Mapping%20global%20and%20local%20coevolution%20across%20600%20species%20to%20identify%20novel%20homologous%20recombination%20repair%20genes&amp;author=D.%20Sherill-Rofe&amp;author=D.%20Rahat&amp;author=S.%20Findlay&amp;author=A.%20Mellul&amp;author=I.%20Guberman&amp;volume=29&amp;issue=3&amp;publication_year=2019&amp;pages=439-448&amp;pmid=30718334&amp;doi=10.1101/gr.241414.118&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib24">
<span class="label">24.</span><cite>Lips E.H., Laddach N., Savola S.P., Vollebergh M.A., Oonk A.M., Imholz A.L., Wessels L.F., Wesseling J., Nederlof P.M., Rodenhuis S. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Breast Cancer Res. 2011;13(5):R107. doi: 10.1186/bcr3049.</cite> [<a href="https://doi.org/10.1186/bcr3049" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3262220/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22032731/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Breast%20Cancer%20Res&amp;title=Quantitative%20copy%20number%20analysis%20by%20Multiplex%20Ligation-dependent%20Probe%20Amplification%20(MLPA)%20of%20BRCA1-associated%20breast%20cancer%20regions%20identifies%20BRCAness&amp;author=E.H.%20Lips&amp;author=N.%20Laddach&amp;author=S.P.%20Savola&amp;author=M.A.%20Vollebergh&amp;author=A.M.%20Oonk&amp;volume=13&amp;issue=5&amp;publication_year=2011&amp;pages=R107&amp;pmid=22032731&amp;doi=10.1186/bcr3049&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib25">
<span class="label">25.</span><cite>Alexandrov L.B., Kim J., Haradhvala N.J., Huang M.N., Tian Ng A.W., Wu Y., Boot A., Covington K.R., Gordenin D.A., Bergstrom E.N., et al.  The repertoire of mutational signatures in human cancer. Nature. 2020;578(7793):94–101. doi: 10.1038/s41586-020-1943-3.</cite> [<a href="https://doi.org/10.1038/s41586-020-1943-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7054213/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32025018/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=The%20repertoire%20of%20mutational%20signatures%20in%20human%20cancer&amp;author=L.B.%20Alexandrov&amp;author=J.%20Kim&amp;author=N.J.%20Haradhvala&amp;author=M.N.%20Huang&amp;author=A.W.%20Tian%20Ng&amp;volume=578&amp;issue=7793&amp;publication_year=2020&amp;pages=94-101&amp;pmid=32025018&amp;doi=10.1038/s41586-020-1943-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib26">
<span class="label">26.</span><cite>Cruz C., Castroviejo-Bermejo M., Gutierrez-Enriquez S., Llop-Guevara A., Ibrahim Y.H., Gris-Oliver A., Bonache S., Morancho B., Bruna A., Rueda O.M., et al.  RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018;29(5):1203–1210. doi: 10.1093/annonc/mdy099.</cite> [<a href="https://doi.org/10.1093/annonc/mdy099" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5961353/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29635390/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=RAD51%20foci%20as%20a%20functional%20biomarker%20of%20homologous%20recombination%20repair%20and%20PARP%20inhibitor%20resistance%20in%20germline%20BRCA-mutated%20breast%20cancer&amp;author=C.%20Cruz&amp;author=M.%20Castroviejo-Bermejo&amp;author=S.%20Gutierrez-Enriquez&amp;author=A.%20Llop-Guevara&amp;author=Y.H.%20Ibrahim&amp;volume=29&amp;issue=5&amp;publication_year=2018&amp;pages=1203-1210&amp;pmid=29635390&amp;doi=10.1093/annonc/mdy099&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib27">
<span class="label">27.</span><cite>Telli M.L., Timms K.M., Reid J., Hennessy B., Mills G.B., Jensen K.C., Szallasi Z., Barry W.T., Winer E.P., Tung N.M., et al.  Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764–3773. doi: 10.1158/1078-0432.CCR-15-2477.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-15-2477" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6773427/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26957554/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Homologous%20recombination%20deficiency%20(HRD)%20score%20predicts%20response%20to%20platinum-containing%20neoadjuvant%20chemotherapy%20in%20patients%20with%20triple-negative%20breast%20cancer&amp;author=M.L.%20Telli&amp;author=K.M.%20Timms&amp;author=J.%20Reid&amp;author=B.%20Hennessy&amp;author=G.B.%20Mills&amp;volume=22&amp;issue=15&amp;publication_year=2016&amp;pages=3764-3773&amp;pmid=26957554&amp;doi=10.1158/1078-0432.CCR-15-2477&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib28">
<span class="label">28.</span><cite>Gou R., Dong H., Lin B. Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy. Life Sci. 2020;261 doi: 10.1016/j.lfs.2020.118434.</cite> [<a href="https://doi.org/10.1016/j.lfs.2020.118434" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32941897/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Life%20Sci&amp;title=Application%20and%20reflection%20of%20genomic%20scar%20assays%20in%20evaluating%20the%20efficacy%20of%20platinum%20salts%20and%20PARP%20inhibitors%20in%20cancer%20therapy&amp;author=R.%20Gou&amp;author=H.%20Dong&amp;author=B.%20Lin&amp;volume=261&amp;publication_year=2020&amp;pmid=32941897&amp;doi=10.1016/j.lfs.2020.118434&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib29">
<span class="label">29.</span><cite>Timms K.M., Abkevich V., Hughes E., Neff C., Reid J., Morris B., Kalva S., Potter J., Tran T.V., Chen J., et al.  Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 2014;16(6):475. doi: 10.1186/s13058-014-0475-x.</cite> [<a href="https://doi.org/10.1186/s13058-014-0475-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4308910/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25475740/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Breast%20Cancer%20Res&amp;title=Association%20of%20BRCA1/2%20defects%20with%20genomic%20scores%20predictive%20of%20DNA%20damage%20repair%20deficiency%20among%20breast%20cancer%20subtypes&amp;author=K.M.%20Timms&amp;author=V.%20Abkevich&amp;author=E.%20Hughes&amp;author=C.%20Neff&amp;author=J.%20Reid&amp;volume=16&amp;issue=6&amp;publication_year=2014&amp;pages=475&amp;pmid=25475740&amp;doi=10.1186/s13058-014-0475-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib30">
<span class="label">30.</span><cite>Sztupinszki Z., Diossy M., Krzystanek M., Reiniger L., Csabai I., Favero F., Birkbak N.J., Eklund A.C., Syed A., Szallasi Z. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. NPJ Breast Cancer. 2018;4:16. doi: 10.1038/s41523-018-0066-6.</cite> [<a href="https://doi.org/10.1038/s41523-018-0066-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6028448/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29978035/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=NPJ%20Breast%20Cancer&amp;title=Migrating%20the%20SNP%20array-based%20homologous%20recombination%20deficiency%20measures%20to%20next%20generation%20sequencing%20data%20of%20breast%20cancer&amp;author=Z.%20Sztupinszki&amp;author=M.%20Diossy&amp;author=M.%20Krzystanek&amp;author=L.%20Reiniger&amp;author=I.%20Csabai&amp;volume=4&amp;publication_year=2018&amp;pages=16&amp;pmid=29978035&amp;doi=10.1038/s41523-018-0066-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib31">
<span class="label">31.</span><cite>Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart-Gebhart M., Thurlimann B., Senn H.J. Panel m: Personalizing the treatment of women with early breast cancer: highlights of the St gallen international Expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24(9):2206–2223. doi: 10.1093/annonc/mdt303.</cite> [<a href="https://doi.org/10.1093/annonc/mdt303" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3755334/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23917950/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=Panel%20m:%20Personalizing%20the%20treatment%20of%20women%20with%20early%20breast%20cancer:%20highlights%20of%20the%20St%20gallen%20international%20Expert%20consensus%20on%20the%20primary%20therapy%20of%20early%20breast%20cancer%202013&amp;author=A.%20Goldhirsch&amp;author=E.P.%20Winer&amp;author=A.S.%20Coates&amp;author=R.D.%20Gelber&amp;author=M.%20Piccart-Gebhart&amp;volume=24&amp;issue=9&amp;publication_year=2013&amp;pages=2206-2223&amp;pmid=23917950&amp;doi=10.1093/annonc/mdt303&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib32">
<span class="label">32.</span><cite>Yao L., Liu Y., Li Z., Ouyang T., Li J., Wang T., Fan Z., Fan T., Lin B., Xie Y. HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Ann Oncol. 2011;22(6):1326–1331. doi: 10.1093/annonc/mdq612.</cite> [<a href="https://doi.org/10.1093/annonc/mdq612" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21196440/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=HER2%20and%20response%20to%20anthracycline-based%20neoadjuvant%20chemotherapy%20in%20breast%20cancer&amp;author=L.%20Yao&amp;author=Y.%20Liu&amp;author=Z.%20Li&amp;author=T.%20Ouyang&amp;author=J.%20Li&amp;volume=22&amp;issue=6&amp;publication_year=2011&amp;pages=1326-1331&amp;pmid=21196440&amp;doi=10.1093/annonc/mdq612&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib33">
<span class="label">33.</span><cite>Yuan W., Ni J., Wen H., Shi W., Chen X., Huang H., Zhang X., Lu X., Zhu C., Dong H., et al.  Genomic Scar Score: a robust model predicting homologous recombination deficiency based on genomic instability. BJOG. 2022;129(Suppl 2):14–22. doi: 10.1111/1471-0528.17324.</cite> [<a href="https://doi.org/10.1111/1471-0528.17324" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36485068/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BJOG&amp;title=Genomic%20Scar%20Score:%20a%20robust%20model%20predicting%20homologous%20recombination%20deficiency%20based%20on%20genomic%20instability&amp;author=W.%20Yuan&amp;author=J.%20Ni&amp;author=H.%20Wen&amp;author=W.%20Shi&amp;author=X.%20Chen&amp;volume=129&amp;issue=Suppl%202&amp;publication_year=2022&amp;pages=14-22&amp;pmid=36485068&amp;doi=10.1111/1471-0528.17324&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib34">
<span class="label">34.</span><cite>Li M.M., Datto M., Duncavage E.J., Kulkarni S., Lindeman N.I., Roy S., Tsimberidou A.M., Vnencak-Jones C.L., Wolff D.J., Younes A., et al.  Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American society of clinical oncology, and College of American pathologists. J Mol Diagn. 2017;19(1):4–23. doi: 10.1016/j.jmoldx.2016.10.002.</cite> [<a href="https://doi.org/10.1016/j.jmoldx.2016.10.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5707196/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27993330/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Mol%20Diagn&amp;title=Standards%20and%20guidelines%20for%20the%20interpretation%20and%20reporting%20of%20sequence%20variants%20in%20cancer:%20a%20joint%20consensus%20recommendation%20of%20the%20association%20for%20molecular%20pathology,%20American%20society%20of%20clinical%20oncology,%20and%20College%20of%20American%20pathologists&amp;author=M.M.%20Li&amp;author=M.%20Datto&amp;author=E.J.%20Duncavage&amp;author=S.%20Kulkarni&amp;author=N.I.%20Lindeman&amp;volume=19&amp;issue=1&amp;publication_year=2017&amp;pages=4-23&amp;pmid=27993330&amp;doi=10.1016/j.jmoldx.2016.10.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib35">
<span class="label">35.</span><cite>Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi: 10.3322/caac.21763.</cite> [<a href="https://doi.org/10.3322/caac.21763" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36633525/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=CA%20Cancer%20J%20Clin&amp;title=Cancer%20statistics,%202023&amp;author=R.L.%20Siegel&amp;author=K.D.%20Miller&amp;author=N.S.%20Wagle&amp;author=A.%20Jemal&amp;volume=73&amp;issue=1&amp;publication_year=2023&amp;pages=17-48&amp;pmid=36633525&amp;doi=10.3322/caac.21763&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib36">
<span class="label">36.</span><cite>Kaklamani V.G., Jeruss J.S., Hughes E., Siziopikou K., Timms K.M., Gutin A., Abkevich V., Sangale Z., Solimeno C., Brown K.L., et al.  Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer ( <a href="https://clinicaltrials.gov/ct2/show/NCT01372579" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01372579</a>) Breast Cancer Res Treat. 2015;151(3):629–638. doi: 10.1007/s10549-015-3435-y.</cite> [<a href="https://doi.org/10.1007/s10549-015-3435-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26006067/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Breast%20Cancer%20Res%20Treat&amp;title=Phase%20II%20neoadjuvant%20clinical%20trial%20of%20carboplatin%20and%20eribulin%20in%20women%20with%20triple%20negative%20early-stage%20breast%20cancer%20(NCT01372579)&amp;author=V.G.%20Kaklamani&amp;author=J.S.%20Jeruss&amp;author=E.%20Hughes&amp;author=K.%20Siziopikou&amp;author=K.M.%20Timms&amp;volume=151&amp;issue=3&amp;publication_year=2015&amp;pages=629-638&amp;pmid=26006067&amp;doi=10.1007/s10549-015-3435-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib37">
<span class="label">37.</span><cite>Telli M.L., Jensen K.C., Vinayak S., Kurian A.W., Lipson J.A., Flaherty P.J., Timms K., Abkevich V., Schackmann E.A., Wapnir I.L., et al.  Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105. J Clin Oncol. 2015;33(17):1895–1901. doi: 10.1200/JCO.2014.57.0085.</cite> [<a href="https://doi.org/10.1200/JCO.2014.57.0085" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4451172/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25847929/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Phase%20II%20study%20of%20gemcitabine,%20carboplatin,%20and%20iniparib%20as%20neoadjuvant%20therapy%20for%20triple-negative%20and%20BRCA1/2%20mutation-associated%20breast%20cancer%20with%20assessment%20of%20a%20tumor-based%20measure%20of%20genomic%20instability:%20PrECOG%200105&amp;author=M.L.%20Telli&amp;author=K.C.%20Jensen&amp;author=S.%20Vinayak&amp;author=A.W.%20Kurian&amp;author=J.A.%20Lipson&amp;volume=33&amp;issue=17&amp;publication_year=2015&amp;pages=1895-1901&amp;pmid=25847929&amp;doi=10.1200/JCO.2014.57.0085&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib38">
<span class="label">38.</span><cite>Weichert W., Lukashchuk N., Yarunin A., Riva L., Easter A., Bannister H., Qiu P., French T. 216 an evaluation of the performance of molecular assays to identify homologous recombination deficiency-positive tumours in ovarian cancer. Int J Gynecol Cancer. 2021;31(Suppl 3):A366. doi: 10.1136/ijgc-2021-ESGO.645.</cite> [<a href="https://doi.org/10.1136/ijgc-2021-ESGO.645" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Gynecol%20Cancer&amp;title=216%20an%20evaluation%20of%20the%20performance%20of%20molecular%20assays%20to%20identify%20homologous%20recombination%20deficiency-positive%20tumours%20in%20ovarian%20cancer&amp;author=W.%20Weichert&amp;author=N.%20Lukashchuk&amp;author=A.%20Yarunin&amp;author=L.%20Riva&amp;author=A.%20Easter&amp;volume=31&amp;issue=Suppl%203&amp;publication_year=2021&amp;pages=A366&amp;doi=10.1136/ijgc-2021-ESGO.645&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib39">
<span class="label">39.</span><cite>Sun J., Meng H., Yao L., Lv M., Bai J., Zhang J., Wang L., Ouyang T., Li J., Wang T., et al.  Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients. Clin Cancer Res. 2017;23(20):6113–6119. doi: 10.1158/1078-0432.CCR-16-3227.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-16-3227" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28724667/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Germline%20mutations%20in%20cancer%20susceptibility%20genes%20in%20a%20large%20series%20of%20unselected%20breast%20cancer%20patients&amp;author=J.%20Sun&amp;author=H.%20Meng&amp;author=L.%20Yao&amp;author=M.%20Lv&amp;author=J.%20Bai&amp;volume=23&amp;issue=20&amp;publication_year=2017&amp;pages=6113-6119&amp;pmid=28724667&amp;doi=10.1158/1078-0432.CCR-16-3227&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib40">
<span class="label">40.</span><cite>O'Shaughnessy J., Brezden-Masley C., Cazzaniga M., Dalvi T., Walker G., Bennett J., Ohsumi S. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. Breast Cancer Res. 2020;22(1):114. doi: 10.1186/s13058-020-01349-9.</cite> [<a href="https://doi.org/10.1186/s13058-020-01349-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7590609/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33109210/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Breast%20Cancer%20Res&amp;title=Prevalence%20of%20germline%20BRCA%20mutations%20in%20HER2-negative%20metastatic%20breast%20cancer:%20global%20results%20from%20the%20real-world,%20observational%20BREAKOUT%20study&amp;author=J.%20O'Shaughnessy&amp;author=C.%20Brezden-Masley&amp;author=M.%20Cazzaniga&amp;author=T.%20Dalvi&amp;author=G.%20Walker&amp;volume=22&amp;issue=1&amp;publication_year=2020&amp;pages=114&amp;pmid=33109210&amp;doi=10.1186/s13058-020-01349-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib41">
<span class="label">41.</span><cite>Marquard A.M., Eklund A.C., Joshi T., Krzystanek M., Favero F., Wang Z.C., Richardson A.L., Silver D.P., Szallasi Z., Birkbak N.J. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res. 2015;3:9. doi: 10.1186/s40364-015-0033-4.</cite> [<a href="https://doi.org/10.1186/s40364-015-0033-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4443545/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26015868/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomark%20Res&amp;title=Pan-cancer%20analysis%20of%20genomic%20scar%20signatures%20associated%20with%20homologous%20recombination%20deficiency%20suggests%20novel%20indications%20for%20existing%20cancer%20drugs&amp;author=A.M.%20Marquard&amp;author=A.C.%20Eklund&amp;author=T.%20Joshi&amp;author=M.%20Krzystanek&amp;author=F.%20Favero&amp;volume=3&amp;publication_year=2015&amp;pages=9&amp;pmid=26015868&amp;doi=10.1186/s40364-015-0033-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib42">
<span class="label">42.</span><cite>Imanishi S., Naoi Y., Shimazu K., Shimoda M., Kagara N., Tanei T., Miyake T., Kim S.J., Noguchi S. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC. Breast Cancer Res Treat. 2019;174(3):627–637. doi: 10.1007/s10549-018-05120-9.</cite> [<a href="https://doi.org/10.1007/s10549-018-05120-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30607631/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Breast%20Cancer%20Res%20Treat&amp;title=Clinicopathological%20analysis%20of%20homologous%20recombination-deficient%20breast%20cancers%20with%20special%20reference%20to%20response%20to%20neoadjuvant%20paclitaxel%20followed%20by%20FEC&amp;author=S.%20Imanishi&amp;author=Y.%20Naoi&amp;author=K.%20Shimazu&amp;author=M.%20Shimoda&amp;author=N.%20Kagara&amp;volume=174&amp;issue=3&amp;publication_year=2019&amp;pages=627-637&amp;pmid=30607631&amp;doi=10.1007/s10549-018-05120-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib43">
<span class="label">43.</span><cite>Yiannakopoulou E. Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications. Cell Oncol (Dordr) 2014;37(1):1–8. doi: 10.1007/s13402-013-0158-0.</cite> [<a href="https://doi.org/10.1007/s13402-013-0158-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24306927/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Oncol%20(Dordr)&amp;title=Etiology%20of%20familial%20breast%20cancer%20with%20undetected%20BRCA1%20and%20BRCA2%20mutations:%20clinical%20implications&amp;author=E.%20Yiannakopoulou&amp;volume=37&amp;issue=1&amp;publication_year=2014&amp;pages=1-8&amp;pmid=24306927&amp;doi=10.1007/s13402-013-0158-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib44">
<span class="label">44.</span><cite>Matis T.S., Zayed N., Labraki B., de Ladurantaye M., Matis T.A., Camacho Valenzuela J., Hamel N., Atayan A., Rivera B., Tabach Y., et al.  Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families. NPJ Breast Cancer. 2021;7(1):109. doi: 10.1038/s41523-021-00315-8.</cite> [<a href="https://doi.org/10.1038/s41523-021-00315-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8387362/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34433815/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=NPJ%20Breast%20Cancer&amp;title=Current%20gene%20panels%20account%20for%20nearly%20all%20homologous%20recombination%20repair-associated%20multiple-case%20breast%20cancer%20families&amp;author=T.S.%20Matis&amp;author=N.%20Zayed&amp;author=B.%20Labraki&amp;author=M.%20de%20Ladurantaye&amp;author=T.A.%20Matis&amp;volume=7&amp;issue=1&amp;publication_year=2021&amp;pages=109&amp;pmid=34433815&amp;doi=10.1038/s41523-021-00315-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib45">
<span class="label">45.</span><cite>Momozawa Y., Sasai R., Usui Y., Shiraishi K., Iwasaki Y., Taniyama Y., Parsons M.T., Mizukami K., Sekine Y., Hirata M., et al.  Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol. 2022;8(6):871–878. doi: 10.1001/jamaoncol.2022.0476.</cite> [<a href="https://doi.org/10.1001/jamaoncol.2022.0476" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9011177/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35420638/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol&amp;title=Expansion%20of%20cancer%20risk%20profile%20for%20BRCA1%20and%20BRCA2%20pathogenic%20variants&amp;author=Y.%20Momozawa&amp;author=R.%20Sasai&amp;author=Y.%20Usui&amp;author=K.%20Shiraishi&amp;author=Y.%20Iwasaki&amp;volume=8&amp;issue=6&amp;publication_year=2022&amp;pages=871-878&amp;pmid=35420638&amp;doi=10.1001/jamaoncol.2022.0476&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib46">
<span class="label">46.</span><cite>Sikov W.M., Berry D.A., Perou C.M., Singh B., Cirrincione C.T., Tolaney S.M., Kuzma C.S., Pluard T.J., Somlo G., Port E.R., et al.  Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance) J Clin Oncol. 2015;33(1):13–21. doi: 10.1200/JCO.2014.57.0572.</cite> [<a href="https://doi.org/10.1200/JCO.2014.57.0572" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4268249/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25092775/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Impact%20of%20the%20addition%20of%20carboplatin%20and/or%20bevacizumab%20to%20neoadjuvant%20once-per-week%20paclitaxel%20followed%20by%20dose-dense%20doxorubicin%20and%20cyclophosphamide%20on%20pathologic%20complete%20response%20rates%20in%20stage%20II%20to%20III%20triple-negative%20breast%20cancer:%20CALGB%2040603%20(Alliance)&amp;author=W.M.%20Sikov&amp;author=D.A.%20Berry&amp;author=C.M.%20Perou&amp;author=B.%20Singh&amp;author=C.T.%20Cirrincione&amp;volume=33&amp;issue=1&amp;publication_year=2015&amp;pages=13-21&amp;pmid=25092775&amp;doi=10.1200/JCO.2014.57.0572&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib47">
<span class="label">47.</span><cite>Ma D., Chen S.Y., Ren J.X., Pei Y.C., Jiang C.W., Zhao S., Xiao Y., Xu X.E., Liu G.Y., Hu X., et al.  Molecular features and functional implications of germline variants in triple-negative breast cancer. J Natl Cancer Inst. 2021;113(7):884–892. doi: 10.1093/jnci/djaa175.</cite> [<a href="https://doi.org/10.1093/jnci/djaa175" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33151324/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Natl%20Cancer%20Inst&amp;title=Molecular%20features%20and%20functional%20implications%20of%20germline%20variants%20in%20triple-negative%20breast%20cancer&amp;author=D.%20Ma&amp;author=S.Y.%20Chen&amp;author=J.X.%20Ren&amp;author=Y.C.%20Pei&amp;author=C.W.%20Jiang&amp;volume=113&amp;issue=7&amp;publication_year=2021&amp;pages=884-892&amp;pmid=33151324&amp;doi=10.1093/jnci/djaa175&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib48">
<span class="label">48.</span><cite>Fasano G.A., Bayard S., Chen Y., Marti J., Simmons R., Swistel A., Bensenhaver J., Davis M., Newman L. Survival outcomes in women with unilateral, triple-negative, breast cancer correlated with contralateral prophylactic mastectomy. Ann Surg Oncol. 2023 doi: 10.1245/s10434-022-13056-0.</cite> [<a href="https://doi.org/10.1245/s10434-022-13056-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36681737/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Surg%20Oncol&amp;title=Survival%20outcomes%20in%20women%20with%20unilateral,%20triple-negative,%20breast%20cancer%20correlated%20with%20contralateral%20prophylactic%20mastectomy&amp;author=G.A.%20Fasano&amp;author=S.%20Bayard&amp;author=Y.%20Chen&amp;author=J.%20Marti&amp;author=R.%20Simmons&amp;publication_year=2023&amp;pmid=36681737&amp;doi=10.1245/s10434-022-13056-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><span>Multimedia component 1</span></div>
<div class="media p" title="Multimedia component 1"><div class="caption">
<a href="/articles/instance/10165146/bin/mmc1.docx" data-ga-action="click_feat_suppl" class="usa-link">mmc1.docx</a><sup> (17.6KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="caption p"><span>Multimedia component 2</span></div>
<div class="media p" title="Multimedia component 2"><div class="caption">
<a href="/articles/instance/10165146/bin/mmc2.docx" data-ga-action="click_feat_suppl" class="usa-link">mmc2.docx</a><sup> (44.3KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material3_reqid_"><div class="caption p"><span>Multimedia component 3</span></div>
<div class="media p" title="Multimedia component 3"><div class="caption">
<a href="/articles/instance/10165146/bin/mmc3.xlsx" data-ga-action="click_feat_suppl" class="usa-link">mmc3.xlsx</a><sup> (28.4KB, xlsx) </sup>
</div></div></section></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from The Breast : Official Journal of the European Society of Mastology are provided here courtesy of <strong>Elsevier</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1016/j.breast.2023.04.002"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/main.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (3.1 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/10165146/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/10165146/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC10165146%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC10165146/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC10165146/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC10165146/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/37116400/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC10165146/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/37116400/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC10165146/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/10165146/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="DZw5fKlJ5oh35ecLaYLcyQgTLGT2mRoqf9Wi1COhm6LngkHMqX9M5Y9zSyifpCTV">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
